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Advisory Professor: Radhe Mohan, Ph.D.

Proton therapy is a radiotherapy modality that can offer a better physical dose
distribution when compared to photon radiotherapy by taking advantage of the Bragg peak, a
narrow region of rapid energy loss. Proton therapy is also known to offer an enhanced relative
biological effectiveness (RBE) compared to photons. In the current clinical standard, RBE is
fixed at 1.1 at all points along the proton beam, meaning protons are assumed to require 10%
less dose than photons to achieve target coverage and organ at risk (OAR) sparing. However,
there is mounting clinical evidence, and a significant number of in vitro experiments, that show
RBE varies, typically as a function of dose averaged linear energy transfer (LETD).

There are two goals of this work. The first is to develop a novel method to model proton
RBE by using the microdosimetric kinetic model (MKM). The MKM requires a quantity called
dose mean lineal energy (𝑦𝑦𝐷𝐷 ), which is analogous to LETD, to model RBE. In this work, a novel
method to calculate 𝑦𝑦𝐷𝐷 is proposed, based on the proton energy spectrum at a location, and
Monte Carlo simulations of microdosimetry. The second goal of this work is to implement

MKM into a treatment planning system to assess the theoretical clinical impact of including
variable RBE during treatment plan optimization.
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This work presents a method to calculate 𝑦𝑦𝐷𝐷 and model the RBE of several proton RBE

experiments. The variable RBE of these experiments was modeled more accurately by MKM
than previously proposed phenomenological models. However, a clear superiority over an

LETD-based model was not demonstrated. In a treatment planning exercise, including variable
RBE modeling into the optimization algorithm led to increased target coverage while
maintaining the dose sparing of OARs. Based on the parameters chosen for the MKM, this led
to an increase in physical dose delivered to the brainstem, and when reanalyzed assuming an
RBE = 1.1, led to doses beyond tolerance. In conclusion, this work presents a novel method to
compute 𝑦𝑦𝐷𝐷 for input into the MK model, and demonstrates slight potential benefits of

considering a variable RBE in treatment plan optimization.
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Chapter 1: Introduction
1.1 Proton therapy
Proton therapy is a radiotherapy treatment modality whereby protons are accelerated to
high energies and then used to irradiate a tumor. Robert Wilson, a physicist at Harvard
University, first proposed proton therapy in 1946 [1]. Wilson proposed that protons be used for
therapy due their unique physical characteristic, the Bragg peak. As protons are transported
through a medium, they gradually lose energy. This energy loss is quantified by stopping power
S. After the proton has lost most of its initial kinetic energy, stopping power rapidly increases
with continued energy loss, until all kinetic energy is lost. The rapid increase in stopping power
results in the Bragg peak, a narrow region with large amounts of energy deposited. Wilson
proposed that several proton energies be used to create a spread-out Bragg peak (SOBP), which
can provide adequate dose distribution across a target volume. A schematic comparing single
Bragg peaks, a spread out Bragg peak and the depth-dose curve for an MV photon beam is
shown in Fig. 1. When comparing the depth-dose curve of protons to photons the physical
advantage of protons becomes clear. Photon beams are characterized by having a dose peak at
relatively shallow depths with a long “tail” that extends beyond the depth of the patient. The
physical nature of photons means there is significant dose to tissue upstream and downstream
from the target. Contrast this to a proton SOBP, which results in rapid dose fall off over a few
millimeters at the beam’s distal edge. Theoretically this means that a critical structure such as
the heart, spinal cord or brain stem could be placed in close proximity to the SOBP.

1

Figure 1: Comparison of proton and photon depth-dose
curves.
Multiple pristine Bragg peaks (blue solid lines) are irradiated
onto a target to achieve a spread out Bragg peak (blue dashed
line). The various heights of the pristine beams indicate each
beam is given a different weight to ensure a flat SOBP. This
image “Comparison_of_dose_profiles_for_proton_v._xray_radiotherapy.png” by MarkFilipak is licensed under CC
BY-SA 3.0
(https://en.wikipedia.org/wiki/File:Comparison_of_dose_profile
s_for_proton_v._x-ray_radiotherapy.png).

1.2 Relative biological effectiveness
There is also a radiobiological rationale for using proton therapy: protons have an
increased biological effectiveness compared to photons. This is quantified with relative
biological effectiveness (RBE), defined as the ratio of doses for two different radiation types to
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reach the same biological endpoint. Convention dictates that the reference radiation dose goes in
the numerator, and the proton dose in the denominator, resulting in an RBE value greater than 1.
𝑅𝑅𝑅𝑅𝑅𝑅 =

𝐷𝐷𝑟𝑟𝑟𝑟𝑟𝑟
𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

(1)

Currently in clinical practice, proton RBE is assumed to be 1.1 at all points along the Bragg
curve. However Paganetti showed, according to most cell survival experiments, RBE values for
proton therapy vary along the Bragg curve. RBE in the entrance region is ~1.1, rising to ~1.15
in the Bragg peak and SOBP, and increasing to ~1.35 in the distal edge and ~1.7 in the distal
falloff region [2]. While wide variations in RBE are observed, Paganetti concluded that on
average, for most of the Bragg curve, the RBE has a value of ~1.1. RBE is typically modeled as
a function of dose-averaged linear energy transfer (LETD), a physical quantity that is
straightforward to calculate with Monte Carlo simulations such as GATE [3, 4], FLUKA [5],
GEANT4 [6] or TOPAS [7] or analytical functions [8, 9]. Clinical proton beams typically have
LETD values that reach a maximum around 20-25 keV/µm. In this range, most data show a
linear relationship of RBE as a function of LETD [10]. As summarized by Grün et al, most
RBE(LETD) experiments have been measured in regions where the LET distribution is relatively
narrow [11]. However, as noted by Grün et al and Mohan et al, in regions such as an SOBP or
overlapping fields, the LET distribution may be broad and the RBE(LETD) relationship is no
longer linear [11, 12].
Clinical evidence of variable proton RBE is scarce but concerning. Peeler et al analyzed
a set of pediatric ependymoma patients who had T2-FLAIR hyperintensity regions in MR
images after proton therapy and showed that these regions are highly correlated with increased
LET, and therefore increased RBE [13]. A paper published after the National Cancer Institute
(NCI) hosted a workshop on radiobiological issues in charged particle therapy noted that as the
3

number of patients treated with proton therapy increases, so do the reports of unexpected
toxicities [14]. In another NCI workshop, brainstem injuries in pediatric patients undergoing
proton therapy were discussed and recommendations were made for modifying treatment plans
in order to reduce these injuries [15]. Underwood et al showed in a cohort of lung cancer
patients receiving proton therapy that RBE exceeded 1.1 based on follow up CT scans that
showed increased lung tissue density [16]. These examples should make it clear that the topic of
proton biological effectiveness should be further studied, and eventually should be taken into
account when creating the proton treatment plans of the future.
1.3 Scope of Dissertation and Specific Aims
In current clinical practice, the relative biological effectiveness (RBE) of proton beams
is assumed to be 1.1 at all points along the Bragg curve. However, several recent experiments
have shown that the RBE of therapeutic proton beams can be as high as 2 or greater in the
region distal to the Bragg peak [17-19]. This RBE is significantly different than the standard
clinical practice of using a constant RBE of 1.1, meaning the tissue in the region distal to the
Bragg peak is receiving significantly more damage. At present, there has been limited work
showing that the microdosimetric kinetic model (MKM) can be used to predict such high RBEs
in proton therapy.
Accurate prediction of the RBE at each point along the Bragg curve would enable
biologically-optimized treatment plans, which have the potential to offer improved treatments
for proton therapy patients. By quantifying the RBE at all points along the proton beam, clinical
physicists will be able to place the most damaging parts of the beam within the target and take
full advantage of proton therapy’s biological dose distribution. MKM is a first-principle model
that predicts cell survival based on dose deposition on a scale of micrometers, and has been used
to model carbon ion RBE, but has not yet been applied clinically to proton therapy. The central
4

goal of this project is to determine how well MKM can accurately predict RBE in the high LET
region of the proton beam and to develop a treatment planning system that implements MKM to
predict proton RBE. The following Specific Aims will address this central goal:
Aim One: Evaluate the accuracy of phenomenological RBE models in the Bragg peak and
distal falloff region. Several RBE models have already been proposed, which typically model
RBE as a linear function of LET. However, recent RBE data shows strong evidence that RBE
may in fact be a nonlinear function of LET, especially beyond the Bragg peak. The hypothesis
for this Aim is: in the high linear energy transfer (LET) region at and beyond the Bragg peak,
phenomenological RBE models will underestimate RBE by at least 20%. This Aim will
determine the applicability of phenomenological RBE models in the high LET region and
possibly demonstrate the need for a model that accurately predicts the high RBEs in these
regions.
Aim Two: Optimize the microdosimetric parameters to achieve a best fit for observed RBE data
based on the MKM. I propose a method to calculate microdosimetric quantities that uses the
proton energy spectrum at various locations along the Bragg curve, based on calculations using
the Geant4 DNA toolkit. The method will be tested with three data sets, consisting of seven total
experiments across three different proton beamlines. I hypothesize this MK model will predict
the RBEs at all points along the proton beam, including the Bragg peak and distal falloff
regions, within experimental uncertainties. This Aim will also obtain the optimal parameters for
fitting MKM to experimental data, demonstrating the best fit achievable using MKM.
Aim Three: Develop a variable RBE prediction functionality in a treatment planning system for
proton therapy. The goal of this Aim is to implement the MKM into matRad, an open-source
treatment planning system that allows the user to access all radiation calculations and even add
5

their own functionalities to the software. Successful completion of this Aim would enable a
treatment planning system to biologically optimize a proton therapy treatment plan, a feature
needed clinically, but not yet developed. Treatment plans optimized using a variable RBE will
be compared to those optimized with a constant 1.1 RBE to investigate whether variable RBE
plans can improve the therapeutic ratio.
The work described above will develop a method for using experimental biological data
and microdosimetry to predict RBE in a treatment planning system for proton therapy. In
current proton therapy treatment, variable RBE is not considered, likely resulting in an overdosing of tissues at and distal to the Bragg peak. This project is innovative in that it seeks to
bring variable RBE prediction into clinical use, a capability that has not been realized, and has
the potential to lead to better patient outcomes by placing the most biologically damaging
regions of the proton beam into the target volumes.

6

Chapter 2: Methods and Materials
This chapter is based upon a paper reprinted from International Journal of Radiation
Oncology*Biology*Physics, Vol. 104, Issue 2, Mark Newpower, Darshana Patel, Lawrence
Bronk, Fada Guan, Pankaj Chaudhary, Stephen J. McMahon, Kevin M. Prise, Giuseppe
Schettino, David R. Grosshans, Radhe Mohan, Using the Proton Energy Spectrum and
Microdosimetry to Model Proton Relative Biological Effectiveness, Pages 316-324 Copyright
2019 with Permission from Elsevier. 2019,ISSN 0360-3016,
https://doi.org/10.1016/j.ijrobp.2019.01.094.
(http://www.sciencedirect.com/science/article/pii/S0360301619301853)

2.1 RBE Data
The RBE data used in this work have been previously published by Chaudhary et al,
Guan and Bronk et al and Patel and Bronk et al [17-19]. In each of these three data sets the
authors performed cell survival experiments and fit the clonogenic cell survival data for protons
and photon beams with the linear quadratic (LQ) model. These model parameters were then
used to calculate RBE at various cell survival levels (i.e. 10%, 50%, etc.). These experiments
were performed on three different beamlines: at the Proton Therapy Center Houston (PTCH) at
MD Anderson Cancer Center [18], at Centro di AdroTerapia Applicazioni Nucleari Avanzate
(CATANA) in Catania, Italy [17], and at the Heidelberg Ion Therapy Center (HIT) in
Heidelberg, Germany [19]. For each experiment the LETD was calculated at each RBE
measurement point to enable modeling RBE as a function of LETD. The experiments by Guan
and Bronk et al and Patel and Bronk et al were done only along a pristine Bragg peak, while
Chaudhary et al used both a pristine Bragg peak and an SOBP for their experiments. Four cell
7

lines were utilized in these studies: AGO1522 and U87 (Chaudhary et al), H460 and H1437
(Guan and Bronk et al), while Patel and Bronk et al performed a very similar RBE experiment
to Guan and Bronk et al, with only H460 cells. The 𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 values for each study are

presented in Table 1. For all RBE calculations in this work, RBE was calculated at the 10%
clonogenic survival level.
Table 1: 𝜶𝜶𝒙𝒙 and 𝜷𝜷𝒙𝒙 parameters for RBE data.

The 𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 parameters shown here were taken from the
RBE studies. These values are used an input in RBE model
calculations.
Cell line
Guan and Bronk et al [18]
H460
H1437
Patel and Bronk et al [19]
H460
Chaudhary et al [17]
AGO1522
U87

𝜶𝜶𝒙𝒙 [Gy-1]
0.290
0.05

𝜷𝜷𝒙𝒙 [Gy-2]
0.083
0.041

0.290

0.083

0.54
0.110

0.062
0.06

2.2 RBE models
Despite Paganetti’s conclusion that RBE should remain fixed at 1.1 for now, there is
mounting clinical evidence that assuming an RBE = 1.1 in treatment planning leads to image
changes along the proton beam’s distal edge. Peeler et al. showed these MR image changes are
well correlated with high LET regions in children treated for ependymoma [13]. Underwood et
al. demonstrated the distal edge region of the proton beam corresponds to increased Hounsfield
Unit changes in CT scans of lung patients following radiation therapy, and linked these changes
to an RBE > 1.1 [16]. Therefore there is a clinical interest in understanding how RBE varies
along the path of the proton beam. If clinical physicists were able to model a variable RBE in
the treatment planning system, then treatment plans could be optimized to deliver high RBE
8

radiation to the target tissue and spare normal tissue with low RBE radiation. Several
phenomenological RBE models have been proposed [20] and three are summarized below.
The model proposed by Wedenberg et al [21] assumes a constant value for β, while α is
linearly dependent on LETD, a fitting parameter 𝑞𝑞 and the x-ray α/β ratio (α/β )𝑥𝑥 :
𝛼𝛼 = 𝛼𝛼𝑥𝑥 �1 +

𝑞𝑞𝐿𝐿𝐿𝐿𝐿𝐿𝑑𝑑
�
(α/ β )𝑥𝑥

(2)

The value for 𝑞𝑞 was found by fitting across 10 cell lines and has a value of 0.434 Gy µm/keV.

The value for 𝑞𝑞 is assumed to be the same regardless of cell type or the physical characteristic of
the proton beam. Wedenberg et al caution, however, that this equation is not valid for LETD
higher than 30 keV/ µm.
The RBE model proposed by Carabe-Fernandez et al takes into account RBE’s
dependence on LET in the 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 terms and is also based on the LQ model [22,
23]. The coefficients in the model’s 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 terms were determined via linear

regression of previously published RBE experiments. This RBE model also requires as input
the physical proton dose, which will be set to 1.8 Gy throughout this work.
α
𝑅𝑅𝑅𝑅𝑅𝑅 �𝐷𝐷𝑝𝑝 , � � , 𝐿𝐿𝐿𝐿𝐿𝐿𝐷𝐷 �
β 𝑥𝑥

1
α 2
α
α
=
�� � � + 4𝐷𝐷𝑝𝑝 � � 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 + 4𝐷𝐷𝑝𝑝2 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 2 − � � �
2𝐷𝐷𝑝𝑝
β 𝑥𝑥
β 𝑥𝑥
β 𝑥𝑥
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(3)

𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 = 0.843 + 1.54
𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 = 1.09 + 0.006

2.686
𝐿𝐿𝐿𝐿𝑇𝑇𝐷𝐷
𝛼𝛼
� �
𝛽𝛽 𝑥𝑥

2.686
𝐿𝐿𝐿𝐿𝑇𝑇𝐷𝐷
𝛼𝛼
� �
𝛽𝛽 𝑥𝑥

(4)

(5)

McNamara, Schuemann and Paganetti [24] developed an RBE model based on the
concepts of 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑖𝑖𝑛𝑛 and 𝑅𝑅𝑅𝑅𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚 proposed by Carabe et al [22] as well as on a dependence on

�(α/ β )𝑥𝑥 proposed by Jones [25]. Like the Carabe-Fernandez model, this model requires the
physical proton dose as input, and is set to 1.8 Gy throughout this work. The McNamara et al
model has the form:
α
𝑅𝑅𝑅𝑅𝑅𝑅 �𝐷𝐷𝑝𝑝 , � � , 𝐿𝐿𝐿𝐿𝐿𝐿𝐷𝐷 �
β 𝑥𝑥

(6)

α
1 ⎛ α 2
α
𝑝𝑝1
2 �𝑝𝑝 + 𝑝𝑝
�
=
�
�
+
4𝐷𝐷
�
�
�𝑝𝑝
+
𝐿𝐿𝐿𝐿𝐿𝐿
�
+
4𝐷𝐷
� 𝐿𝐿𝐿𝐿𝐿𝐿𝐷𝐷
�
�
𝑝𝑝
0
𝐷𝐷
𝑝𝑝
2
3
α
β 𝑥𝑥
2𝐷𝐷𝑝𝑝 ⎜ β 𝑥𝑥
β 𝑥𝑥
� �
β 𝑥𝑥
⎝
α ⎞
− � � ⎟
β 𝑥𝑥
⎠

The fitting coefficients 𝑝𝑝0 − 𝑝𝑝3 were found to be: 𝑝𝑝0 = 0.999064 (standard error) (SE) 0.014125,

𝑝𝑝1= 0.35605 (SE 0.015038), 𝑝𝑝2 = 1.1012 (SE 0.0059972), and 𝑝𝑝3 = -0.0038703 (SE 0.00091303),
with a R2 value of 0.255. The McNamara model was shown to predict RBE values well at low

LETD. However at higher LETD values (~18.7 keV/µm), the model predicts a lower RBE than
measured experimentally by Guan and Bronk et al.
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To facilitate comparison to the microdosimetric kinetic model (MKM) a generic LETD
based model with a single fitting parameter was proposed:
𝛼𝛼𝑝𝑝 = 𝛼𝛼𝑥𝑥 + 𝑘𝑘 × 𝐿𝐿𝐿𝐿𝑇𝑇𝐷𝐷

(7)

This model assumes 𝛽𝛽 is constant for both proton and X-ray beams. The 𝑘𝑘 parameter was varied

to achieve a best fit with the experimental RBE data. This generic RBE model enabled a

comparison to the MKM because both models have one free fitting parameter. The method to
compare the MKM and generic RBE model is outlined in section 2.5.
A first-principle approach to predicting cell survival known as the microdosimetric
kinetic model (MKM) was proposed by Hawkins [26, 27]. His work built upon the theory of
dual radiation action, developed by Kellerer and Rossi, and Zaider and Rossi [28, 29]. As its
name implies, MKM uses the concepts of microdosimetry, the study and quantification of
spatial and temporal distributions of absorbed energy in irradiated matter [30, 31]. The central
concept of microdosimetry is the domain, a spherical volume of unit density. The radius of the
domain (𝑟𝑟𝑑𝑑 ) is typically on the order of 0.5 µm. The domain is defined as the distance a DNA
lesion can travel through the nucleus before it is repaired [27]. Thus, the domain is a cell-

specific parameter that depends on the cell’s ability to repair damage to its DNA. If the domain
is placed randomly near an ion track, there is a probability that energy will be deposited inside
it. The simplest microdosimetric quantity is specific energy 𝑧𝑧, which has units of J/kg, or Gray,
and can be considered as a stochastic equivalent of absorbed dose [30]. Specific energy can be

averaged in two ways: frequency-averaged and dose-averaged, 𝑧𝑧𝐹𝐹 and 𝑧𝑧𝐷𝐷 , respectively. Another
quantity of interest is lineal energy 𝑦𝑦, which is defined as the quotient of the energy deposited
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into the domain 𝜀𝜀 by a primary particle, with mean chord length 𝑙𝑙 through that volume,
expressed in Eq. 8.

𝑦𝑦 =

𝜀𝜀

(8)

𝑙𝑙

Lineal energy has units of keV/µm. In the same way as specific energy, the lineal energy
frequency distribution function can be used to calculate frequency averaged (𝑦𝑦𝐹𝐹 ) and dose

averaged (𝑦𝑦𝐷𝐷 ) lineal energy. The single event distributions of specific energy (𝑓𝑓(𝑧𝑧)) and lineal
energy (𝑓𝑓(𝑦𝑦)) are used to compute frequency and dose averaged specific and lineal energy in
the following way:
∞

(9)

∞

(10)

𝑧𝑧𝐹𝐹 = � 𝑧𝑧𝑧𝑧(𝑧𝑧)𝑑𝑑𝑑𝑑
0

𝑦𝑦𝐹𝐹 = � 𝑦𝑦𝑦𝑦(𝑦𝑦)𝑑𝑑𝑑𝑑
0

∞

(11)

∞

(12)

∫0 𝑧𝑧 2 𝑓𝑓(𝑧𝑧)𝑑𝑑𝑑𝑑
𝑧𝑧𝐷𝐷 =
𝑧𝑧𝐹𝐹

∫0 𝑦𝑦 2 𝑓𝑓(𝑦𝑦)𝑑𝑑𝑑𝑑
𝑦𝑦𝐷𝐷 =
𝑦𝑦𝐹𝐹

The quantity 𝑦𝑦𝐷𝐷 is particularly important in the MK model when used to model ion irradiation

survival experiments. It is the stochastic quantity in microdosimetry that corresponds to LETD.
Both LETD and 𝑦𝑦𝐷𝐷 are used as measures of radiation quality and as a surrogate for biological

response. For proton therapy studies this work used the MKM equations presented by Kase et al
[32]. The MKM follows the linear-quadratic model with 𝛼𝛼 and 𝛽𝛽 coefficients for dose and the
square of the dose, respectively. The MKM is written as follows
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ln(𝑆𝑆𝑆𝑆) = 𝛼𝛼𝛼𝛼 + 𝛽𝛽𝐷𝐷2
𝛼𝛼𝑝𝑝 = 𝛼𝛼𝑥𝑥 + 𝛽𝛽𝑥𝑥
𝛽𝛽𝑝𝑝 = 𝛽𝛽𝑥𝑥

𝑦𝑦𝐷𝐷
𝜋𝜋𝜋𝜋𝑟𝑟𝑑𝑑2

(13)

(14)
(15)

where 𝑆𝑆𝑆𝑆 is the survival fraction, 𝑦𝑦𝐷𝐷 is the dose-mean lineal energy, 𝜌𝜌 is the mass density of

water and the subscripts 𝑝𝑝 and 𝑥𝑥 denote protons and x-rays, respectively. The MKM assumes

that regardless of the radiation type, the 𝛽𝛽 term is constant. The MK model assumes that 𝛼𝛼0 is

the slope of the survival curve in the limit of LET =0, but in this work, 𝛼𝛼𝑥𝑥 is used rather than 𝛼𝛼0 ,
as the reference radiation 𝛼𝛼 parameter. LET for the reference radiation is assumed to be low
enough that 𝛼𝛼 variations for the reference radiation is negligible, making 𝛼𝛼0 appropriate.
2.3 Calculating 𝒚𝒚𝑫𝑫 and fitting MKM to experimental data

To input microdosimetric values such as 𝑦𝑦𝐷𝐷 into the MKM, they must be measured, such

as with a tissue-equivalent proportional counter (TEPC) or calculated. This subchapter will

propose a method to calculate 𝑓𝑓(𝑦𝑦) using the Geant4 DNA toolkit. Then a method to calculate

𝑦𝑦𝐷𝐷 based on the proton energy spectrum and lineal energy probability density functions (𝑓𝑓(𝑦𝑦))

will be presented. Finally the least-squares fitting of the MK model to experimental data will be
described.
2.3.1 Computational Resources
All Monte Carlo and Matlab computations done in this work were performed on either
the Nautilus or Seadragon clusters at the MD Anderson Cancer Center. The Nautilus cluster had
over 300 compute nodes, and each node was a BL465c G7 blade with two 12-core AMD 6174
processors, for a total of 12 cores per node. Each code had at minimum, 64 GB RAM.
Nautilus’s operating system was Red Hat Enterprise Linux 6.5 with a queueing interface
consisting of PBS/Torque and Moab. Seadragon is MD Anderson’s newest cluster, consisting of
13

204 compute nodes with 27 CPU cores per node, and 192 GB RAM per node. Seadragon uses
Red Hat Enterprise 7.4 as its operating system and uses the Spectrum Load Sharing Facility 10.1
software for job scheduling.
2.3.2 Geant4 DNA
The DNA extension to the Geant4 Monte Carlo simulation toolkit is designed to enable
modeling of ionizing radiation at the scale of DNA in liquid water [6, 33-36]. In order to model
radiation interactions with matter on the scale of nanometers, unique particle physics models
have been developed for increased accuracy at low energies, on the order of hundreds of eV.
These models are essential to calculate the energy loss of protons at low, although relevant
energies for proton therapy around 1 MeV. As with any Monte Carlo system, the settings for the
simulation are important. This work used all the default settings provided in the Geant4 DNA
10.2.0 release, except for the secondary particle range cut value. This range cut refers to the
minimum range a secondary particle must have in order to be transported by the Monte Carlo
code. If an ionized electron has a range below the cut value the electron and all its kinetic
energy is deposited locally without being transported. For protons with kinetic energies > 2
MeV, the cut length was left at 1000 nm. For protons ≤ 2 MeV the cut length was set to 5 nm.
The different cut lengths will be explained in section 2.3.3. Simulations were created to
transport protons through a cube of liquid water with 5 µm side lengths. 295 proton energies
were simulated, with up to 100 unique tracks simulated per energy. The range of energies for
protons was [0.1, 223] MeV, which covered the energy spectrum of the proton machine at the
Proton Therapy Center Houston. The output of the simulation included, for all primary and
secondary particles, the position in 3 dimensions, kinetic energy, event type, and parent track.
This allowed the reconstruction of the path and kinetic energy of the primary proton through the
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water cube, as well as the path and kinetic energies of all ionized electrons and other secondary
particles.
2.3.3 Calculating 𝑦𝑦 and 𝑓𝑓(𝑦𝑦)

A Matlab script was developed to take the output of the Geant4 DNA and reconstruct the

3D map of the proton’s track through the water cube, along with the position and energy of
secondary particles. The script placed spheres with radii of 500 nm at random points at and
along the proton track. The script determined if energy was deposited into a sphere, and how
much, computing 𝜀𝜀 from Eq. 8. The mean chord length 𝑙𝑙 was calculated via Cauchy’s formula to
be

𝑙𝑙 = 4(𝑉𝑉/𝑆𝑆)

(16)

where 𝑉𝑉 is the volume and 𝑆𝑆 is the surface area of the sphere. Thus for each randomly-placed

sphere the lineal energy deposited in that sphere was calculated. The scored 𝑦𝑦 values were then
binned, with a range of [0.01, 300] keV/µm and 0.1 keV/µm bin widths. The result of these

binned lineal energy values is a histogram, which is the function 𝑓𝑓(𝑦𝑦) for that proton energy.

Because the 𝑦𝑦 values scored 𝑛𝑛 times were used to compute 𝑦𝑦𝐷𝐷 , which is a sum over all scored

values according to Eq. 12, the fractional error in each bin was assumed to follow a Poissonian
distribution:

𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 =

�𝑛𝑛 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑛𝑛 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

(17)

The total fractional error for the 𝑓𝑓(𝑦𝑦) of a single proton energy was the quadrature sum of the
fractional error of each lineal energy bin. The total number of scored spheres were increased
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until the total maximum fractional error for any 𝑓𝑓(𝑦𝑦) was < 1.5 × 10-4 for protons <100 MeV.

For protons with energies > 100 MeV the number of samples per track was set to 500.

For protons with energies > 2 MeV, the vast majority of ionized electrons had kinetic
energies that enabled them to travel further than 1000 nm, the default cut length in the Geant4
DNA “dnaphysics” example. However for protons ⪅ 2 MeV, a significant fraction of ionized
electrons did not have enough kinetic energy to go beyond 1000 nm, but did have enough

energy to travel beyond the 500 nm radius of the domain, and thus the Geant4 code deposited
the kinetic energy of the particle locally. The result of using the 1000 nm cut length for protons
with energies ≥ 2 MeV were 𝑦𝑦𝐷𝐷 values that were 2-3 times greater than what was expected,

based on previously published work by Nikjoo et al and Lindborg et al [37] [38]. Based on these
results, all track files for proton energies ≥ 2 MeV were re-simulated and the lineal energy and
𝑓𝑓(𝑦𝑦) re-calculated. The resulting 𝑦𝑦𝐷𝐷 values then agreed much closer to Nikjoo et al and
Lindborg et al’s values.

2.3.4 Calculating 𝑦𝑦𝐷𝐷 of a polyenergetic proton beam

The rate that an ion loses kinetic energy in a micrometer sized volume is not constant.

Rather, it follows a probability distribution 𝑓𝑓(𝑦𝑦). This stochastic nature of energy loss must be

accounted for in microdosimetry, hence the use of averaged quantities such as 𝑦𝑦𝐷𝐷 . In the case of

a proton beam passing through a patient, particularly at the Bragg peak, the 𝑦𝑦𝐷𝐷 value includes

energy loss characteristics of a broad energy distribution. It is with this understanding that the
following method for calculating 𝑦𝑦𝐷𝐷 was conceived. For each energy 𝑖𝑖, by weighting the

constituent 𝑓𝑓(𝑦𝑦)𝑖𝑖 by its fluence 𝛷𝛷(𝐸𝐸)𝑖𝑖 at a particular point, the probability density function of a
polyenergetic proton beam (𝑓𝑓𝑤𝑤 (𝑦𝑦)) can be calculated by Eq. 18.
16

𝑓𝑓𝑤𝑤 (𝑦𝑦) =

∑𝑖𝑖 𝛷𝛷(𝐸𝐸)𝑖𝑖 𝑓𝑓(𝑦𝑦) 𝑖𝑖
∑𝑖𝑖 𝛷𝛷(𝐸𝐸)𝑖𝑖

(18)

The 𝑦𝑦𝐷𝐷 of a polyenergetic proton beam is thus:
𝑦𝑦𝐷𝐷 =

∫ 𝑦𝑦 2 𝑓𝑓𝑤𝑤 (𝑦𝑦) 𝑑𝑑𝑑𝑑
∫ 𝑦𝑦𝑓𝑓𝑤𝑤 (𝑦𝑦) 𝑑𝑑𝑑𝑑

(19)

2.4 Fitting 𝒓𝒓𝒅𝒅 and calculating RBE

Once 𝑦𝑦𝐷𝐷 was calculated, the radius of the domain 𝑟𝑟𝑑𝑑 from Eq. 14 was varied to reach the

best agreement with the experimental RBE. The best 𝑟𝑟𝑑𝑑 was found using the least squares

method when RBE is modeled as a function of 𝑦𝑦𝐷𝐷 . The value of 𝑟𝑟𝑑𝑑 was expected to vary by

only 200-300 nm at most, and such a difference in the domain size compared to the calculated
𝑦𝑦𝐷𝐷 using 𝑟𝑟𝑑𝑑 = 500 nm via Geant4 DNA will not change the underlying 𝑓𝑓(𝑦𝑦) distribution

significantly. Thus it was appropriate to use the 𝑓𝑓(𝑦𝑦) values calculated with Geant4 DNA. To
calculate the RBE of the MK model Eq. 20 was used:

𝑅𝑅𝑅𝑅𝑅𝑅 =

�𝛼𝛼𝑥𝑥2 − 4𝛽𝛽𝑥𝑥 𝑙𝑙𝑙𝑙 𝑆𝑆𝑆𝑆 − 𝛼𝛼𝑥𝑥

�𝛼𝛼𝑝𝑝2 − 4𝛽𝛽𝑝𝑝 𝑙𝑙𝑙𝑙 𝑆𝑆𝑆𝑆 − 𝛼𝛼𝑝𝑝

×

𝛽𝛽𝑝𝑝
𝛽𝛽𝑥𝑥

(20)

The subscripts 𝑝𝑝 and 𝑥𝑥 in Eq. 20 refer to proton and X-ray 𝛼𝛼 and 𝛽𝛽 parameters, respectively.

𝛼𝛼𝑝𝑝 and 𝛽𝛽𝑝𝑝 are calculated from Eq. 14 and 15, and 𝛼𝛼𝑥𝑥 and 𝛽𝛽𝑥𝑥 are from the LQ fitting parameters

of the reference X-ray radiation. 𝑆𝑆𝑆𝑆 refers to the survival fraction of the clonogenic cell survival

experiments, and was set to 0.1 in this work. Eq. 20 was obtained by solving for the dose terms
in the LQ equations and taking the ratio of those doses according to Eq. 1.
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2.5 Comparing RBE models
The hypothesis of Specific Aim One was phenomenological RBE models will underpredict RBE by 20% in the Bragg peak and distal falloff region. The percentage difference
between the RBE model and experimental data was calculated by Eq. 21:
% 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 − 𝑡𝑡ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
× 100
𝑡𝑡ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

(21)

The generic RBE model in Eq. 7 uses LETD as a measure of radiation quality. Authors
such as Mohan et al [12] and Grün et al [11] have argued that dose-averaged LET may not be
the most reliable indicator of biological effect. They argue that in theory, for a proton beam with
a broad energy distribution such as that found near and distal to the Bragg peak, the low energy
(and thus high LET) portion of the proton energy spectrum will kill cells more efficiently than
the higher energy (and thus lower LET) portion. Averaging LET values based on dose could
lead to breakdowns in the assumed linear relationship between LET and RBE. A comparison of
MKM, with its radiation quality measured by 𝑦𝑦𝐷𝐷 and the generic RBE model with radiation

quality in LETD would be useful to determine if one model is superior to the other. The Akaike
Information Criterion (AIC) analysis method quantitatively compared the MKM with the
generic RBE model. AIC analysis compares two models used to fit data and determines which
of the two models fits better based on their respective sum of squares. Eq. 22 and Eq. 23 express
how the relative likelihood (𝑅𝑅𝑅𝑅) that the worse-fitting model better represents the data is

calculated. The terms 𝑆𝑆𝑆𝑆1 and 𝑆𝑆𝑆𝑆2 are the sum of squares from each model fit. The values for
𝑆𝑆𝑆𝑆1 and 𝑆𝑆𝑆𝑆2 were chosen so that 𝑆𝑆𝑆𝑆2 > 𝑆𝑆𝑆𝑆1. In Eq. 22 𝑁𝑁 is the number of experimental RBE

points to compare the models to.

𝑆𝑆𝑆𝑆2
∆𝐴𝐴𝐴𝐴𝐴𝐴 = 𝑁𝑁 × ln �
�
𝑆𝑆𝑆𝑆1
18

(22)

𝑅𝑅𝑅𝑅 = exp(−∆𝐴𝐴𝐴𝐴𝐴𝐴/2 )

(23)

2.6 matRad
MatRad is a treatment planning system written in Matlab [39]. It enables the user to
create optimized radiotherapy treatment plans with photons and ions such as protons and
carbon. MatRad includes functions for a graphical user interface (GUI), to import DICOM CT
data, to optimize treatment plans based on dose objectives, and for carbon ions, it includes a
biological optimization option which uses the LEM IV model [40]. A screenshot of the matRad
GUI is shown in Fig. 2. Due to being written in Matlab the entire code is open source and the
user can modify the underlying functions as they wish. MatRad also supports users creating
their own beamlines. For this work, the matRad code used for this work was downloaded on
April 5, 2018. Matlab R2017b was used to run matRad. The scanning beamline in use at PTCH,
known as G3, was commissioned into matRad. The data for G3 was taken from Monte Carlo
data that was validated against measurements. G3 has 94 proton beam energies, from 72.5 MeV
to 221.8 MeV, corresponding to ranges of 4 cm to 30.6 cm [41].
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Figure 2: matRad GUI
MatRad has many of the basic functionalities of commercial treatment planning systems,
including defining optimization settings. The treatment plan shown comes standard with the
matRad download.
There are significant concerns for brainstem toxicities in patients with ependymoma receiving
proton radiotherapy [13-15]. In theory, the smaller the (α/β )𝑥𝑥 ratio is, the greater the RBE [2,
23]. As expressed by Lühr et al, tissues most affected by variable RBE should be late

responding tissues (low (α/β )𝑥𝑥 ratio) that receive low to intermediate doses and are located

distal to the target [42]. The brainstem is just such a critical structure and thus, an ependymoma
patient planning CT would make an ideal test case to investigate the efficacy of optimizing
treatment plans using a variable RBE.
2.6.1 Incorporating MKM optimization into matRad
The MK model requires the calculation of 𝑦𝑦𝐷𝐷 to compute 𝛼𝛼𝑝𝑝 and therefore RBE (Eqs.

12, 14, 20). Based on the number of voxels in a modern treatment planning CT (~10-20 ×106) it
20

is not computationally feasible to compute the proton energy spectrum in each voxel and apply
Eq. 19 to calculate RBE during the optimization process, which can require hundreds of
RBE×Dose calculations. Therefore the method to calculate RBE by Inaniwa et al for carbon
beam therapy in Japan was adopted for this work [43]. In their paper, Inaniwa et al adopted the
∗
MK model proposed by Kase et al by calculating 𝑧𝑧1𝐷𝐷
, or the saturation-corrected dose mean

specific energy of the domain delivered in a single event [32]. Carbon ion therapy requires a
saturation correction for LETs > ~150 keV/μm, where RBE reaches a maximum and further
increases in LET result in a decreasing RBE, called the overkill effect. This overkill effect is not
present in proton therapy and therefore there needs to be no saturation correction for a treatment
∗
was
planning system using the MK model for proton therapy. In the paper by Inaniwa et al 𝑧𝑧1𝐷𝐷

calculated by combining the contributions from individual carbon beamlets:

∗
(𝑧𝑧1𝐷𝐷
𝑚𝑚𝑚𝑚𝑚𝑚 )𝑖𝑖

=

𝑁𝑁

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
∗ )
∑𝑗𝑗=1
𝑤𝑤𝑗𝑗 ∙ 𝑑𝑑𝑖𝑖𝑖𝑖 ∙ (𝑧𝑧1𝐷𝐷
𝑖𝑖𝑖𝑖

(24)

𝑁𝑁

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
∑𝑗𝑗=1
𝑤𝑤𝑗𝑗 ∙ 𝑑𝑑𝑖𝑖𝑖𝑖

∗ )
where (𝑧𝑧1𝐷𝐷
𝑖𝑖𝑖𝑖 is the saturation-corrected dose mean specific energy of the domain at position 𝑖𝑖

delivered by beam 𝑗𝑗, and 𝑁𝑁𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 is the number of beam spots in the treatment plan. 𝑤𝑤𝑗𝑗 represents

the weight of spot 𝑗𝑗 and 𝑑𝑑𝑖𝑖𝑖𝑖 is the dose at point 𝑖𝑖 from beam 𝑗𝑗. During optimization, the values
of 𝑤𝑤𝑗𝑗 are varied to achieve target coverage and organ at risk (OAR) sparing. The approach

implemented into matRad followed this same calculation in Eq. 24, except 𝑦𝑦𝐷𝐷 was be calculated
∗
instead of 𝑧𝑧1𝐷𝐷
. From Kase et al, 𝑧𝑧1𝐷𝐷 (the dose mean specific energy, not saturation corrected) is

related to 𝑦𝑦𝐷𝐷 by:

𝑦𝑦𝐷𝐷
𝜌𝜌𝜌𝜌𝑟𝑟𝑑𝑑2

𝑧𝑧1𝐷𝐷 =

(25)

where 𝑟𝑟𝑑𝑑 is the radius of the domain. In this work the dose mean lineal energy of a mixed proton
field at position 𝑖𝑖 with the number of spots 𝑁𝑁𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 and beam 𝑗𝑗 was calculated by Eq. 26.
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�𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 � =
𝑖𝑖

𝑁𝑁

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
∑𝑗𝑗=1
𝑤𝑤𝑗𝑗 ∙ 𝐷𝐷𝑖𝑖𝑖𝑖 ∙ (𝑦𝑦𝐷𝐷 )𝑖𝑖𝑖𝑖

(26)

𝑁𝑁

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
∑𝑗𝑗=1
𝑤𝑤𝑗𝑗 ∙ 𝐷𝐷𝑖𝑖𝑖𝑖

In matRad the dose to a point 𝑖𝑖 from pencil beam 𝑗𝑗 is calculated by the matrix multiplication of

the dose influence matrix 𝐷𝐷𝑖𝑖𝑖𝑖 and the weight 𝑤𝑤 of pencil beam 𝑗𝑗. Casting this as a matrix vector
�⃗ is the a
product �𝒅𝒅⃗ = 𝐷𝐷𝒘𝒘
���⃗ takes advantage of Matlab’s speed in matrix multiplication, where 𝒅𝒅

vector with the dose to every voxel, from every beam. Therefore including the (𝑦𝑦𝐷𝐷 )𝑖𝑖𝑖𝑖 term in
Eq. 26 was conceptually straightforward.

To implement the 𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 calculation, the 𝑦𝑦𝐷𝐷 at each depth for every proton beam

energy must be calculated. To do this, the proton energy spectrum at 1 mm intervals in depth,
for all 94 beams in G3 was simulated using a MCNPX model of the beamline [44]. The 𝑦𝑦𝐷𝐷 at

every mm was calculated using Eq. 18 and Eq. 19, using the 𝑓𝑓(𝑦𝑦) calculated from Geant4 DNA

simulations presented in sections 2.3.2 and 2.3.3. The results of these calculations were saved in
a file called yD_table_MDA_G3.mat for later use in calculating 𝑦𝑦𝐷𝐷 at a given depth for every
beam energy. Figure 3 shows a screenshot of the yD_table_MDA_G3.mat data. The public

version of matRad does not currently feature the ability to incorporate variable RBE in proton
treatment plan optimization. However this functionality was added by modifying the matRad
source code. In the default dose calculation function called
matRad_calcParticleDose.mat, the dose from every pencil beam to every voxel in the
planning CT is calculated. By default, this data is not available to the user, as the total dose to
all voxels from all beams is the output of the function. A copy of
matRad_calcParticleDose.mat called
matRad_calcParticleDose_MKM_optimization.mat was created in order to save, as
output, the dose from each pencil beam to each voxel. This enabled the separation of each pencil
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Figure 3: yD_table_MDA_G3.mat format
This data table enables the calculation of 𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 for the
G3 beamline. 𝑦𝑦𝐷𝐷 values as a function of depth are
interpolated based on this data. There is also an entry for
the maximum depth of the beam. All 𝑦𝑦𝐷𝐷 values beyond
this depth are set to 0.
beam’s contribution to the total dose in a voxel, which is used in Eq. 26. During the
optimization process, the vector of weights (𝑤𝑤𝑗𝑗 ) of each pencil beam 𝑗𝑗 was varied until the dose
constraints and objectives were solved to an acceptable level. For each iteration the function

matRad_calcParticleDose_MKM_optimization.mat was called because as the pencil
beam weights changed, each pencil beam’s dose contribution to a voxel changed. The process to
recalculate the dose contributions from each pencil beam to each voxel takes approximately two
to four minutes, and is a major contributor to the slowness of the MKM optimization process in
matRad.
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The MKM optimization functionality written into matRad is summarized as follows.
Inside the optimization function, a function called matRad_backProjection.mat is called
to calculate the current dose distribution, which is then evaluated via the optimizer’s objective
function for conformity to plan constraints and objectives. matRad_backProjection.mat
calls MKM_RBE_Calculator.mat which then calls
matRad_calcParticleDose_MKM_optimization.mat, which calculates the dose
contribution from each pencil beam to every voxel. The output of this function is a data
structure called dij_MKM. This is then used as input into a function called
yD_doseAvg_calculation_beams.mat was written to calculate �𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 � according to Eq.
𝑖𝑖

26. This function in turn called calculateProtonRBEFromyD.mat, a function written to
calculate the RBE in all voxels of the planning CT. The output of

calculateProtonRBEFromyD.mat is a matrix named MKM_RBE_cube with dimensions
𝑋𝑋 × 𝑌𝑌 × 𝑍𝑍, where 𝑋𝑋, 𝑌𝑌, and 𝑍𝑍 are the number of voxels in the planning CT in the respective

coordinate axes. MKM_RBE_cube was then multiplied by the physical dose distribution to get
the RBE-weighted dose (RWD) distribution. The RWD distribution was then evaluated for
adherence to the dose constraints and objectives. This process was repeated until the dose
constraints and objectives were met. Fig. 4 is a flowchart of the optimization process. For this
project MKM_RBE_Calculator.mat, yD_doseAvg_calculation_beams.mat and
calculateProtonRBEFromyD.mat were newly written functions, while
matRad_backProjection.mat and
matRad_calcParticleDose_MKM_optimization.mat were functions provided by
matRad that were modified to perform variable RBE optimization.
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Figure 4: RBE optimization implemented into matRad.
This flowchart demonstrates the implementation of calculating RBE via the MK model in
matRad. Functions called by the optimization process end in .m, and are shown in black
rectangles. The output of these functions are shown as blue parallelograms.

2.6.2 Patient data
As presented in section 1.2 and Refs 13-15, there are significant concerns about
brainstem toxicities with pediatric ependymoma patients. The treatment planning CT from a
patient treated at the PTCH was used to evaluate the clinical effect of incorporating variable
RBE as calculated by the MK model into intensity modulated proton therapy (IMPT) treatment
plans. The patient was treated on the G3 scanning beamline. The OAR and target contours and
simulation CT were imported into matRad. The beam angles chosen in matRad were identical to
those used for treatment at PTCH, and consisted of three beams. Gantry angles were 110°, 180°
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and 250°, and the couch angle for each beam was 0°. The distance between spots was set to 9
mm. Planning objectives in matRad were guided by constraints given in Table 2. The GTV was
prescribed 1.8 Gy(RBE) per fraction for 30 fractions, for a total target prescription of 54
Gy(RBE) to the GTV. The constraints and dose prescriptions are the same as those used by a
current MD Anderson internal trial for ependymoma patients.
Table 2: Organ at risk constraints for ependymoma patients.
OAR

Constraint

Optic nerves (ON)
Optic chiasm (OC)
Brainstem

Max ≤ 55 Gy(RBE)
Max ≤ 55 Gy(RBE)
D10% < 55.4 Gy(RBE)
D50% < 52.4 Gy(RBE)
V50 < 61.7%
V55 < 17.7%
D0.1cc < 56.6 Gy(RBE)
Max ≤ 50 Gy(RBE)
Max 45 Gy(RBE)

Spinal cord
Eye, including retina

Once all the dose constraints were met, and the GTV received as close to 100% of the 54
Gy(RBE) prescription dose as possible without exceeding OAR tolerance doses, the treatment
plan was deemed acceptable for MKM optimization. The equivalent uniform dose (EUD) to the
brainstem was then calculated and the normal tissue complication probability (NTCP)
computed, using the parameters outlined in section 2.6.3.
2.6.3 Radiobiological properties of tissues during MKM optimization
The 𝛼𝛼0 and 𝛽𝛽 values for each tissue were the same ones assigned by Frese et al in their

RBE analysis, which was taken from a PhD dissertation by Cronqvist [45, 46]. 𝛼𝛼0 is used rather
than 𝛼𝛼𝑥𝑥 to be consistent with the MKM laid out by Kase et al, where 𝛼𝛼0 is the initial survival

curve slope in the limit of LET=0. The 𝛼𝛼0 values presented by Frese are corrected from the 𝛼𝛼𝑥𝑥
values by assuming LET in the experiments from which 𝛼𝛼𝑥𝑥 was determined is approximately
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0.5 keV/μm. Using either 𝛼𝛼0 or 𝛼𝛼𝑥𝑥 is assumed to have a negligible effect on the RBE value.
Therefore the α/β ratios given in Table 3 are not exactly 10 Gy or 2 Gy, but slightly less.

However the 𝛼𝛼𝑥𝑥 / 𝛽𝛽𝑥𝑥 ratio given by Frese are exactly 10 Gy or 2 Gy. The value for 𝑟𝑟𝑑𝑑 in the GTV
and CTV was set to 243 nm. This was chosen based on the fitted value for the AGO1522 cell
line in the SOBP irradiations. AGO1522 has an α/β ratio of 8.7 Gy, which is the closest
experimental value to the assumed tumor α/β ratio of 10 Gy. For all other tissues, since they
have an α/β ratio of 2 Gy, 𝑟𝑟𝑑𝑑 was set to 461 nm. This is also based on fitting a cell line, in this

case the U87 SOBP experiment, as the U87 α/β ratio is 1.83 Gy. Table 3 gives the assumed
parameters used during RBE calculations in this work.
Table 3: Radiobiological properties of tissues for RBE optimization
α/β (Gy)

Tumor (GTV, CTV)

10

𝜶𝜶𝟎𝟎 (Gy-1)
0.1084

𝜷𝜷 (Gy-2)

Brainstem

2

0.0492

0.0266

Spinal cord

2

0.0367

0.0203

Optic nerves

2

0.0256

0.0471

Optic chiasm

2

0.0256

0.0471

Eyes

2

0.0367

0.0203

Brain

2

0.0580

0.0310

Tissue

0.0112

To estimate the normal tissue complication probability (NTCP) for the brainstem,
equivalent uniform dose (EUD) and Niemierko’s NTCP/TCP model was used [47] [48]. EUD is
calculated by
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𝐸𝐸𝐸𝐸𝐸𝐸 =

1
𝑎𝑎

(27)

��(𝑣𝑣𝑖𝑖 𝐷𝐷𝑖𝑖𝑎𝑎 )�
𝑖𝑖=1

where 𝑣𝑣𝑖𝑖 is the 𝑖𝑖’th volume receiving dose 𝐷𝐷𝑖𝑖 , and 𝑎𝑎 is a unitless parameter that corresponds to
the tumor or normal tissue. NTCP is calculated by
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 =

1

(28)
4𝛾𝛾50

𝑇𝑇𝐷𝐷50
1 + � 𝐸𝐸𝐸𝐸𝐸𝐸
�

In Eq. 28, 𝑇𝑇𝐷𝐷50 corresponds to the tolerance dose that results in 50% of a population

experiencing a complication, and 𝛾𝛾50 is a parameter that describes the slope of the dose-

response curve, and is unique to each tissue. Using the NTCP/TCP tool published by Gay and
Niemierko, brainstem EUD and NTCP were calculated [49]. Setting the 𝑎𝑎 parameter in the EUD
calculation to a large positive number will skew the EUD towards the maximum dose to a

structure. The maximum dose is important to a serial organ such as the brainstem, as the most
difficult planning constraint to meet is to keep the dose to 0.1 cc of the brainstem below 56.6
Gy(RBE). Thus for brainstem EUD, the 𝑎𝑎 = 25. As recommended by Niemierko, 𝛾𝛾50 was set to

4 and TD50 was set to 65 Gy [49].

2.6.4 Comparing standard treatment plans to MKM optimized plans
To assess the impact of including variable RBE during treatment plan optimization, a
treatment plan optimized using the standard RBE=1.1 paradigm was compared to a treatment
plan optimized using the MK model for variable RBE. A radiation oncologist reviewed these
plans and deemed them clinically realistic. Treatment plan DVHs and NTCPs for the brainstem
will be compared. There will be three DVHs and three NTCPs; one each from the std_opt,
std_opt_MKM_calc, and MKM_opt plans. These plans are defined in the workflow below:
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1) Patient planning CT, OARs and target contours are imported into matRad. Optimization
objectives are also set.
2) A treatment plan assuming a constant RBE=1.1 is created and optimization objectives
varied until OAR constraints are met and the plan is approved by a radiation oncologist
as clinically realistic. This standard treatment plan is saved and is known as the std_opt
plan.
3) The variable RBE using MKM is calculated on std_opt. The variable RBE result is then
saved as well. This is known as the std_opt_MKM_calc plan.
4) The variable RBE, MKM-calculated standard treatment plan (std_opt_MKM_calc) is
used as the starting point for an MKM-optimized treatment plan. This resulting MKMoptimized plan is then saved. This plan is known as the MKM_opt plan.
One purpose of this workflow was to first create a realistic treatment plan with the RBE=1.1
model (std_opt) and then calculate the variable RBE and RWD (std_opt_MKM_calc) to
evaluate the potential dangers in using a constant RBE. RWD hot spots are expected in critical
structures such as the brainstem and spinal cord, and in normal brain tissue. The second purpose
of this workflow was to take the std_opt_MKM_calc plan and optimize it using a variable RBE
calculated via the MK model. It is hypothesized that by including the MK model in the
optimization algorithm, another clinically realistic treatment plan can be created (MKM_opt)
that should both increase target coverage and reduce normal issue toxicity as compared to the
std_opt_MKM_calc plan.
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Chapter 3: Results
This chapter is based upon a paper reprinted from International Journal of Radiation
Oncology*Biology*Physics, Vol. 104, Issue 2, Mark Newpower, Darshana Patel, Lawrence
Bronk, Fada Guan, Pankaj Chaudhary, Stephen J. McMahon, Kevin M. Prise, Giuseppe
Schettino, David R. Grosshans, Radhe Mohan, Using the Proton Energy Spectrum and
Microdosimetry to Model Proton Relative Biological Effectiveness, Pages 316-324. Copyright
2019 with Permission from Elsevier. 2019,ISSN 0360-3016,
https://doi.org/10.1016/j.ijrobp.2019.01.094.
(http://www.sciencedirect.com/science/article/pii/S0360301619301853)

3.1 Phenomenological model fitting to experimental RBE data
The phenomenological models proposed by Wedenberg et al [21], Carabe-Fernandez et
al [22], and McNamara et al [24] were applied to the RBE datasets previously published by
Chaudhary et al [17], Guan and Bronk et al [18] and Patel and Bronk et al [19]. The LQ model
parameters used for each cell line are given in Table 1. Fig. 5 shows the RBE models with the
data from Guan and Bronk et al and Chaudhary et al. Fig. 6 shows the RBE models with the
data published by Patel and Bronk et al.
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Figure 5: Phenomenological and generic RBE models applied to the Chaudhary et al
and Guan and Bronk et al data.
Panels a and b show the RBE models and the two cell line data published in Ref. 18.
Panels c-f show the RBE models and cell line data published in Ref. 17. Error bars on
experimental RBE values were calculated by propagating α and β fits from respective
references.
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Figure 6: Models applied to RBE data from Patel and Bronk et al
Phenomenological proton RBE models applied to RBE data published by Patel and Bronk
et al in Ref 19. Error bars were calculated by propagating α and β fits from Ref. 19.

3.2 Difference between phenomenological RBE models and RBE data
The Bragg peak in the Guan and Bronk et al data occurs near the LETD = 10.8 keV/µm
data point, meaning the four highest LET values are in the Bragg peak and distal falloff regions.
Tables 4 and 5 show the results of the phenomenological models’ accuracy in modeling the data
from Guan and Bronk et al.
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Table 4: Guan and Bronk et al H460 data compared to phenomenological RBE models.
The predicted RBE values for each of the three phenomenological RBE models are given, as
well as the percent difference between the models and experimental RBE. A percent difference
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer,
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN:
McNamara RBE model; CF: Carabe-Fernandez RBE model.
LETD Exp.
RBE
10.8 1.28
15.2 1.87
17.7 2.58
19 3.28

Wed
1.48
1.69
1.81
1.89

% diff from
Exp. RBE
-14%
11%
43%
74%

McN
1.47
1.61
1.69
1.74

% diff from
Exp. RBE
-13%
16%
53%
89%

CF
1.53
1.72
1.82
1.87

% diff from
Exp. RBE
-16%
9%
42%
75%

Table 5: Guan and Bronk et al H1437 data compared to phenomenological RBE models.
The predicted RBE values for each of the three phenomenological RBE models are given, as
well as the percent difference between the models and experimental RBE. A percent difference
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer,
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN:
McNamara RBE model; CF: Carabe-Fernandez RBE model.
LETD

10.8
15.2
17.7
19

Exp.
RBE
1.26
1.7
2.33
2.98

Wed
1.35
1.52
1.62
1.67

% diff from
Exp. RBE
-7%
12%
44%
78%

McN
1.63
1.81
1.91
1.69

% diff from
Exp. RBE
-23%
-6%
22%
76%

CF
1.78
2.02
2.15
2.21

% diff from
Exp. RBE
-29%
-16%
8%
35%

In the data from Chaudhary et al, the Bragg peak in the pristine Bragg peak experiments
occurs at the LETD=11.8 keV/µm data point. Table 6 shows the results of the phenomenological
model fittings of the pristine Bragg peak experiments. Chaudhary et al also included RBE
experiments done in an SOBP. The most proximal point in the SOBP was where LETD = 2.6
keV/µm. The results of phenomenological model fittings for the Chaudhary et al SOBP data are
shown in Table 7. The Bragg peak in the Patel and Bronk et al data occurs closest to the
LETD=9.8 keV/µm point. Table 8 shows the results of the phenomenological RBE model
fittings to this data.
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Table 6: Chaudhary et al pristine Bragg peak data compared to phenomenological RBE
models.
The predicted RBE values for each of the three phenomenological RBE models are given, as
well as the percent difference between the models and experimental RBE. A percent difference
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer,
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN:
McNamara RBE model; CF: Carabe-Fernandez RBE model.
LETD Exp.
RBE
11.9 2.45
18 2.66
22.6 3.38

LETD Exp.
RBE
11.9 1.42
18 1.84
22.6 2.15

Wed
1.37
1.56
1.72

Wed
1.48
1.77
2

Pristine Bragg Peak, AGO1522 Cell Line
% diff from
McN
% diff from
Exp. RBE
Exp. RBE
79%
1.3
88%
71%
1.44
85%
97%
1.54
119%
Pristine Bragg Peak, U87 Cell Line
% diff from
McN
% diff from
Exp. RBE
Exp. RBE
-4%
1.62
-12%
4%
1.85
-1%
8%
2.01
7%
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CF
1.3
1.48
1.61

CF
1.75
2.04
2.25

% diff from
Exp. RBE
88%
80%
110%

% diff from
Exp. RBE
-19%
-10%
-4%

Table 7: Chaudhary et al SOBP peak data compared to phenomenological RBE models.
The predicted RBE values for each of the three phenomenological RBE models are given, as
well as the percent difference between the models and experimental RBE. A percent difference
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer,
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN:
McNamara RBE model; CF: Carabe-Fernandez RBE model.
LETD Exp.
RBE
2.6 1.44
4.5 1.69
13.4 1.93
21.7 2.24
25.9 2.75

LETD Exp.
RBE
2.6 1.11
4.5 1.18
13.4 1.27
21.7 1.44
25.9 1.64

Wed
1.08
1.13
1.41
1.69
1.83

Wed
1.09
1.17
1.55
1.95
2.17

SOBP, AGO1522 Cell Line
% diff from
McN
% diff from
Exp. RBE
Exp. RBE
34%
1.09
32%
49%
1.13
50%
37%
1.34
44%
33%
1.52
47%
50%
1.61
71%
SOBP, U87 Cell Line
% diff from
McN
% diff from
Exp. RBE
Exp. RBE
2%
1.20
-8%
1%
1.30
-9%
-18%
1.68
-24%
-26%
1.98
-27%
-24%
2.12
-23%

CF
1.01
1.07
1.35
1.59
1.70

CF
1.20
1.33
1.82
2.21
2.38

% diff from
Exp. RBE
43%
58%
43%
41%
61%

% diff from
Exp. RBE
-8%
-11%
-30%
-35%
-31%

Table 8: Patel and Bronk et al H460 data compared to phenomenological RBE models.
The predicted RBE values for each of the three phenomenological RBE models are given, as
well as the percent difference between the models and experimental RBE. A percent difference
> 0 means the RBE model under-predicted RBE. Abbreviations: LET: linear energy transfer,
units of keV/µm; Exp. RBE: Experimental RBE; Wed: Wedenberg RBE model; McN:
McNamara RBE model; CF: Carabe-Fernandez RBE model.
LETD
9.8
12.3
13.8
15.2
16.8
18.9
20.2

Exp.
RBE
1.39
1.47
1.75
1.78
1.96
2.20
2.54

Wed
1.43
1.55
1.62
1.69
1.77
1.88
1.95

% diff from
Exp. RBE
-2%
-5%
8%
5%
11%
17%
30%

McN
1.43
1.51
1.57
1.61
1.66
1.73
1.77

35

% diff from
Exp. RBE
-3%
-3%
12%
10%
18%
27%
43%

CF
1.48
1.59
1.66
1.72
1.79
1.87
1.92

% diff from
Exp. RBE
-6%
-8%
6%
3%
10%
18%
32%

3.3 Fractional error of Geant4 DNA 𝒇𝒇(𝒚𝒚) scoring method

Due to the stochastic nature of energy deposition on the micrometer scale, the method

for calculating 𝑓𝑓(𝑦𝑦) for each proton energy as outlined in Chapter 2.3.3 is subject to uncertainty.

This uncertainty was quantified with fractional error as expressed in Eq. 17. For this work, 295

proton energies were simulated and their 𝑓𝑓(𝑦𝑦) calculated. The proton energy range for this data

set is [0.1, 223.0] MeV, which covers the relevant energy range for proton therapy performed at
the PTCH. Fig. 7 shows the fractional error for each calculated 𝑓𝑓(𝑦𝑦) and the number of scored
spheres per track to reach that fractional error. Protons with kinetic energies < 100 MeV had a

maximum fractional error of 1.5 × 10-4, while protons with kinetic energy > 100 MeV had a

maximum fractional error of 1 × 10-3.
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Figure 7: Fractional Error, samples per track, and number of tracks sampled using Geant4 DNA
Panel a) shows the total fractional error in each calculated 𝑓𝑓(𝑦𝑦), by using the number of sampled domains per track,
given in panel b). Panel c) shows the total number of tracks used to calculate 𝑓𝑓(𝑦𝑦). The discontinuities at 100 MeV
in panels a) and c) are a result of different ionization models
used by Geant4 DNA. The transition from one model
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to another occurs at 100 MeV. Used by permission from Elsevier.

3.4 Calculating 𝒚𝒚𝑫𝑫

Fig. 8 shows 𝑦𝑦𝐷𝐷 for each of the 𝑓𝑓(𝑦𝑦) calculated via Eq. 19. The plot in Fig. 8 thus

represents the calculated 𝑦𝑦𝐷𝐷 for a purely monoenergetic proton beam. A comparison of these 𝑦𝑦𝐷𝐷
values and those published by Nikjoo et al [37] was made by Newpower et al [50], and they

concluded the 𝑦𝑦𝐷𝐷 between the two studies were very similar, particularly at low proton energies.

The comparison is shown in Fig. 8. In each of the three RBE studies used as experimental data

in this work, the authors calculated the proton energy spectrum at each RBE measurement point.
These spectra were used as input for Eq. 18 and the dose mean lineal energy (𝑦𝑦𝐷𝐷 ) was calculated
via Eq. 19. The results of these calculations are shown in Fig. 9. The linear relationship between
𝑦𝑦𝐷𝐷 and LETD for each beam configuration is shown in each panel.
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Figure 8: 𝒚𝒚𝑫𝑫 values for monoenergetic proton beams

The 𝑦𝑦𝐷𝐷 for each calculated 𝑓𝑓(𝑦𝑦), based on Eq. 12. The discontinuity at 100 MeV
is an artifact of changing ionization models at 100 MeV. The 𝑦𝑦𝐷𝐷 published in
Ref. 37 are shown in red for comparison. This figure is used with permission
from Elsevier.
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Figure 9: Relationship between 𝒚𝒚𝑫𝑫 and LETD

The relationship between radiation qualities 𝑦𝑦𝐷𝐷 and LETD. A linear
relationship between the two radiation qualities was expected. This
figure is used with Permission from Elsevier.
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3.5 Modeling RBE with the generic RBE model and the MK model
The generic RBE model from Eq. 7 was fit to the experimental data by varying 𝑘𝑘 and

inputting the LQ parameters listed in Table 1. By varying 𝑟𝑟𝑑𝑑 and using the 𝑦𝑦𝐷𝐷 calculated via Eq.
18 and Eq. 19 and using the LQ parameters from Table 1, the experimental RBE data was

modeled by the MK model. The results of these fittings is presented in Figs. 10-12. In the panels
of these figures are the fitted 𝑘𝑘 and 𝑟𝑟𝑑𝑑 values. Note that in Figs. 10-12, the abscissa is plotted as

LETD. This is to remain consistent with convention, but the reader should be aware that for the
MK model, RBE is actually a function of 𝑦𝑦𝐷𝐷 and not LETD.

Figure 10: Generic RBE model and MK model applied to Guan and Bronk et al data
Panel a) shows the results of the model fittings for the H460 cell line and panel b) shows the
model fittings for the H1437 cell line. Used with permission from Elsevier.
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Figure 11: Generic RBE model and MK model applied to Chaudhary et al data.
Panels a) and b) show the U87 cell line experiments and model fittings in the pristine
Bragg peak and spread out Bragg peak setups, respectively. Panels c) and d) show the
same fittings for the same irradiation setups with the AGO1522 cell line. Used with
permission from Elsevier.
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Figure 12: Generic RBE model and MK model applied to Patel and Bronk et al
data.
The H460 RBE experiment performed by Patel and Bronk et al. Used with
permission from Elsevier.

3.6 AIC analysis of generic RBE model vs. the MK model
Table 9 shows the results of the AIC analysis to compare the performance of the generic
RBE model and MK model. The relative likelihood from the AIC analysis is the likelihood that
the worse-fitting model (in terms of a larger sum of squares) is actually the better model. MKM
fit the data better in two experiments, and five experiments were fit better with the generic RBE
model.
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Table 9: AIC analysis of generic RBE model vs MK model
Results of the AIC analysis comparing the generic RBE model to the MK model.
The RL indicates the relative likelihood that the worse-fitting model actually is
superior. SS indicates the sum of squares difference between the data and the
model fit.
Cell line
Guan and Bronk et al
H460

H1437

Chaudhary et al
Pristine Bragg peak,
AGO1522

Pristine Bragg peak,
U87

Spread out Bragg
peak, AGO1522

Spread out Bragg
peak, U87

Patel and Bronk et al
H460

MKM
𝑟𝑟𝑑𝑑 = 323 nm
CI=[286.7-379.3]
SS1 = 1.473

Generic
k=0.0621
CI = [0.04798-0.07578]
SS2 = 1.061

RL = 0.140
𝑟𝑟𝑑𝑑 = 310 nm
CI = [274.8-368.8]
SS1 = 1.271
RL = 0.1632

k=0.0330
CI = [0.02511-0.04073]
SS2 = 0.9396
-

𝑟𝑟𝑑𝑑 = 302 nm
CI=[192.4-213.9]
SS2=0.1096
𝑟𝑟𝑑𝑑 =345 nm

k=0.08423
CI=[0.07092-0.09746]
SS1=0.2404
RL = 0.0948
k=0.0285

CI=[311.3-394.7]

CI=[0.02554-0.0313]

SS1=0.1189

SS2=0.02386

RL = 0.0081

-

𝑟𝑟𝑑𝑑 =243 nm

k=0.0537

CI=[227.2-262.8]

CI=[0.03957-0.06765]

SS2=0.1086

SS1=0.3402

-

RL = 0.0325

𝑟𝑟𝑑𝑑 = 461 nm

k=0.0147

CI=[420.0-518.0]

CI=[0.01318-0.0194]

SS2=0.02759

SS1=0.01614

RL = 0.2002

-

𝑟𝑟𝑑𝑑 = 426 nm
CI=[397.5-461.9]
SS1 = 0.3606
RL = 0.0474

k = 0.045
CI=[0.03987-0.0514]
SS2 = 0.2169
-
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3.7 matRad Optimization Results
In order to compute RBE for the MK model, 𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 must be calculated, which requires

the 𝑦𝑦𝐷𝐷 of each beam contributing dose at that location. Figure 13 shows an example of the 𝑦𝑦𝐷𝐷

and integral depth doses for two beams, 88.0 MeV and 181.1 MeV, and is illustrative of the data
used for MKM optimization in matRad.
Following the constraints given in Table 2 and the dose prescription of 54 Gy(RBE) to
the GTV, a treatment plan using RBE=1.1 was created, known as the std_opt plan. The RBEweighted dose (RWD) was recalculated on this treatment plan using the MK model outlined in
section 2.6.1, and is called the std_opt_MKM_calc plan. Finally, a biologically optimized plan
known as MKM_opt was created. Table 10 shows the GTV and CTV coverage as well as the
dose to the brainstem and spinal cord and NTCP estimates for the brainstem for each plan.
Figure 14 shows the DVHs for the std_opt and std_opt_MKM_calc plans. This shows
that hot spots in normal brain tissue appeared, and cold spots appeared in the brainstem when
analyzing the std_opt plan with a variable RBE calculated via the MK model.
During optimization, the dose must be rapidly recalculated for each iteration. In the
standard optimization algorithm (fixed RBE=1.1), each recalculation of the dose and objective
function took approximately 1-3 seconds. During the MK model based optimization, each dose,
RBE and objective function calculation took approximately 6-7 minutes. When running the
RBE optimization algorithm, a typical optimization run would take ~6-17 hours, and require a
maximum of 104 GB of memory.
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Figure 15 shows the RBE distribution of the std_opt_MKM_calc plan. In most of the
brainstem, RBE < 1.1. This is what led to the lower EUD and lower point doses to the brainstem
on the std_opt_MKM_calc plan as shown in Table 10.
Hotspots appeared at the edge of the CTV and in the normal brain tissue just beyond the
CTV when the variable RBE was calculated on the std_opt plan. Figure 16 shows the same CT
slice with a side by side comparison of the std_opt plan and the std_opt_MKM_calc plan. The
hotspot was reduced in the MKM_opt plan, and the result is shown in Fig. 17. The hotspot in the
CTV was reduced, as was the RWD in the region just outside of the CTV.
Table 10: Dose to targets and OARs for IMPT plans
The doses to the optic chiasm, optic nerves and eyes were well below tolerances and are not
shown.
Structure/EUD

std_opt std_opt_MKM_calc MKM_opt

% of GTV getting ≥ 54 Gy(RBE)

88.0

87.7

94.0

GTV EUD [Gy(RBE)]

57.0

57.8

58.3

% of CTV getting ≥ 54 Gy(RBE)

74.1

76.8

76.9

Max spinal cord dose [Gy(RBE)]

49.7

49.0

47.5

Dose to 10% of brainstem [Gy(RBE)]

54.6

52.2

54.0

Dose to 50% of brainstem [Gy(RBE)]

47.6

45.2

46.3

Dose to 0.1cc of the brainstem [Gy(RBE)]

56.2

55.8

56.0

Brainstem EUD [Gy(RBE)]

52.2

51.1

51.7

Brainstem NTCP [%]

2.9

2.0

2.4
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Figure 13: IDDs and 𝒚𝒚𝑫𝑫 as a function of depth for two beams.

The 𝑦𝑦𝐷𝐷 of the beams only increases rapidly near and beyond the Bragg peak.
The bump at 140 mm is an artifact of different ionization models used by
Geant4 DNA for protons at 100 MeV.
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Figure 14: Dose volume histograms of the RBE-weighted doses of the std_opt and
std_opt_MKM_calc plan.
The dashed lines indicate the resulting DVHs when the IMPT plan was optimized using the
constant RBE=1.1 model. Solid lines are the DVHs of that same physical dose distribution
with a variable RBE calculated by the MK model.
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Figure 15: RBE in the brainstem, GTV and CTV as calculated by the MKM
Based on the values for 𝛼𝛼0 , 𝛽𝛽, and 𝑟𝑟𝑑𝑑 , the RBE in the brainstem was mostly < 1.1. This
led to decreased RWD to the brainstem when the RBE is calculated from the MK model
in the std_opt_MKM_calc plan.
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Figure 16: Comparison of std_opt to std_opt_MKM_calc
The RWD distribution for the std_opt plan is shown in panel a. By calculating the variable RBE via MKM, on the std_opt dose
distribution, a hotspot in the CTV appeared (Panel b). There was also an increased RWD region outside of the CTV, as compared to the
std_opt plan.

Figure 17: MKM optimization plan reduces RWD brainstem hotspot
This dose colorwash shows how the RWD in the brainstem is reduced through the MKM-optimized treatment plan. In panel a the RWD
from std_opt_MKM_calc is shown. In panel b is the same location on the MKM_opt plan. The hotspot in the CTV has been reduced, and
in general the higher RWD region is decreased slightly in the vicinity of the CTV.

Figure 18 compares the DVHs of the std_opt_MKM_calc plan to the MKM_opt plan.
This shows increased GTV coverage as well as increased RWD to the brainstem in the
MKM_opt plan. In Figure 19 the 𝑦𝑦𝐷𝐷 distribution from the std_opt plan (calculated in the

std_opt_MKM_calc plan) is shown next to the 𝑦𝑦𝐷𝐷 distribution in the MKM_opt plan. 𝑦𝑦𝐷𝐷 was

reduced in the brainstem and maintained in the GTV and CTV after RBE optimization. Figure
20 shows the physical dose difference between the MKM_opt plan and the std_opt plan. This
figure demonstrates the dose modulation that occurred during the RBE optimization process,
and shows that physical dose was increased into the brainstem and decreased in the GTV and
CTV.
The RWD distribution in the MKM_opt plan was recalculated with the RBE=1.1 model,
and the DVH of the MKM_opt plan with variable and fixed RBE (RBE=1.1) is shown in Fig.
21. Dose-volume parameters of this recalculation are shown in Table 11. To obtain the RWD of
the MKM_opt plan for the RBE=1.1 model, the physical dose in the MKM_opt plan was
multiplied by 1.1.
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Figure 18: DVH comparison of std_opt_MKM_calc and MKM_opt
In this DVH comparison, the solid lines represent the MKM_opt plan and the dashed lines
the std_opt_MKM_calc plan. Note that in this figure, the std_opt_MKM_calc plan is in
dashed lines and the same plan is showed in solid lines in Fig. 14.
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Figure 19: 𝒚𝒚𝑫𝑫 distribution before and after MKM optimization

Panel a shows the 𝑦𝑦𝐷𝐷 distribution in the brainstem, GTV and CTV as calculated on the std_opt plan. Panel b shows the 𝑦𝑦𝐷𝐷 distribution after
MKM optimization. The 𝑦𝑦𝐷𝐷 in the brainstem is reduced in the MKM_opt plan, and therefore RBE in the brainstem decreases accordingly.

Figure 20: Difference in physical dose distributions between std_opt and MKM_opt plan
Both panels show the difference in physical dose in the two optimized plans, std_opt and MKM_opt. The slice in panel a is the same slice
shown in Fig. 15, and the slice in panel b is the same slice shown in Figs. 16, 17 and 19. During the optimization process in the
MKM_opt plan, the physical dose in the brainstem was increased, and the physical dose in the GTV and CTV was decreased by several
Gy in some regions of those structures.

Table 11: DVH metrics for MKM optimized plan analyzed with variable RBE and RBE=1.1
Summary of the DVH metrics of the MKM_opt plan with the variable RBE, and with the
MKM_opt variable RBE with the RWD recalculated using a constant RBE=1.1.
Structure/EUD

MKM_opt, Variable RBE MKM_opt, RBE=1.1

% of GTV getting ≥ 54 Gy(RBE)

94.0

77.5

GTV EUD [Gy(RBE)]

58.3

55.9

% of CTV getting ≥ 54 Gy(RBE)

76.9

59.3

Max spinal cord dose [Gy(RBE)]

47.5

48.6

Dose to 10% of brainstem [Gy(RBE)]

54.0

56.8

Dose to 50% of brainstem [Gy(RBE)]

46.3

48.4

Dose to 0.1cc of the brainstem [Gy(RBE)]

56.0

59.1

Brainstem EUD [Gy(RBE)]

51.7

55.6

Brainstem NTCP [%]

2.4

7.4
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Figure 21: RWD for MKM_opt plan and MKM_opt plan recalculated with RBE = 1.1
The solid lines represent the DVH for the MKM_opt plan (same as the solid lines in Fig. 18).
The dashed lines represent the DVH for the RWD of the MKM_opt plan by assuming RBE =
1.1, not the variable RBE calculated by the MK model.
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Chapter 4: Discussion
4.1 Difference between phenomenological models and experimental RBE data
The phenomenological proton RBE models proposed by Wedenberg et al, McNamara et
al and Carabe-Fernandez et al were applied to experimental data published by Chaudhary et al,
Guan and Bronk et al and Patel and Bronk et al. These model fittings are shown in Fig. 5 and
Fig 6. The percent difference between model predictions and experimental data are shown in
Tables 4-8. The purpose of applying these phenomenological proton RBE models to these
experiments was to determine how well the models predict RBE in the Bragg peak and distal
falloff region.
For both cell lines in the Guan and Bronk et al data the phenomenological models
overestimated RBE close to the Bragg peak, around 10.8 keV/µm, but the models
underestimated RBE at higher LETD (Fig. 5a, 5b). As remarked by McNamara et al and Guan
and Bronk et al, this experimental data shows RBE as a highly nonlinear function of LETD [18,
24]. All three of the presented models fail to account for the nonlinearity of this data set and
therefore no models even follow the same shape as the data. The three models’ accuracy in the
H460 cell line experiments underestimated RBE by greater than 20% only at the highest two
LETD points. The H1437 data was similarly modeled by the phenomenological models, where
RBE underestimation by the models was for the highest two LETD points. The exception to this
was the Carabe-Fernandez model, which overestimated RBE at the Bragg peak by 29%, and
was within 8% at the 17.7 keV/µm LETD point. In conclusion the phenomenological RBE
models poorly model the RBE data in presented by Guan and Bronk et al.
In contrast to the striking nonlinearity of the Guan and Bronk et al data, all of the data
presented by Chaudhary et al and Patel and Bronk et al show a much more linear relationship
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between RBE and LETD (Fig. 5 c-f, Fig. 6). The AGO1522 cell line in both the SOBP and
pristine Bragg peak configuration was not modeled well by the phenomenological models. Each
model under predicted RBE in the Bragg peak and beyond, with up to 110% difference between
the Carabe-Fernandez model and experimental data. In the SOBP the AGO1522 cells (Fig. 5e)
were better modeled by the phenomenological models, although in all cases the models
underestimate RBE by more than 20%. AGO1522 is a normal human fibroblast cell line with a
large (8.7 Gy) α/β ratio. Many malignant tumors are radioresistant and thus have smaller α/β
ratios, and these results show the dangers in assuming the same radiobiological properties across
a range of tissues. Ideally, different radiobiological survival parameters should be applied to
different tissues in treatment planning. The U87 cell line is a radioresistant glioma cell line, and
the phenomenological RBE models predict RBE much better with the U87 cells than the
AGO1522 cells. In the pristine Bragg peak setup on the U87 cells (Fig. 5d), the RBE models
actually overestimate RBE in the low LETD region, but are typically within 10%. In the U87
SOBP setup (Fig. 5f) the RBE models also overestimate RBE, typically by more than 20%.
Overall, phenomenological models do not model the RBE as function of LETD well, save for the
U87 pristine Bragg peak geometry.
In Fig. 10 and Table 8 the comparison of the phenomenological RBE models and RBE
data is presented for the Patel and Bronk et al data. This dataset uses the same cell line, H460, as
presented in Guan and Bronk et al. However the data by Patel and Bronk do not show the same
degree of nonlinearity between RBE and LETD. The reason for the differences in the two
experiments is unclear, but can possibly be related to differences in cell colony counting during
the clonogenic assays between the two studies, and the different Monte Carlo simulation
settings between the two studies. Whatever the cause, the Patel and Bronk et al RBE as a
function of LETD was much more linear. In this data 7 out of 12 experimental measurements
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were done at or beyond the Bragg peak. All three phenomenological models overestimate RBE
for the points closest to the Bragg peak (9.8 and 12.3 keV/µm). After this point RBE models
underestimate RBE. However at only the highest LETD point (20.2 keV/µm) do the RBE
models underestimate the experimental RBE by more than 20%.
4.2 Fitting the generic RBE model to data
The generic RBE model fit the experimental RBE data well, except for the very
nonlinear data published by Guan and Bronk et al. In the Chaudhary et al data, the generic RBE
model fits the pristine Bragg peak data better than the SOBP data, due to that data’s more linear
relationship between LETD and RBE. The generic RBE model and the MK model fittings are
shown in Figs. 10-12. Overall, by fitting the generic RBE model to the data, RBE is modeled
well as a linear function of LETD.
4.3 Uncertainty analysis of Geant4 DNA 𝒇𝒇(𝒚𝒚) scoring method

The uncertainty analysis of the presented Geant4 DNA scoring method to calculate 𝑓𝑓(𝑦𝑦)

(Fig. 7) shows that with enough samples and enough proton tracks, a small amount of fractional
error can be assured. The fractional errors for every 𝑓𝑓(𝑦𝑦) below 1 × 10-3 for protons means that

when 𝑓𝑓(𝑦𝑦) functions are combined as in Eq. 19, the combined fractional error of all the

individual 𝑓𝑓(𝑦𝑦) will be negligible. In Fig. 7c) the number of simulated proton tracks drops from
100 to about 70 and gradually decreases as energy increases. This is due to the change in

physics models mentioned in section 4.4. The physics models used for protons with kinetic
energies > 100 MeV assume that the protons interact with matter much less frequently than the
models used below 100 MeV. Thus when some simulations are carried out by Geant4 DNA, the
result is that the proton had no interactions in the 5 µm sided water cube, and therefore no track
file was written. This was discovered during post-processing of the data. Due to the relatively
low fractional error (Fig. 7a), the missing tracks were not re-simulated. The choice not to re60

simulate this data is supported by the minimal effects these higher energy protons have on the
RBE calculation in the treatment planning cases, as discussed in section 4.7.
4.4 Calculating 𝒚𝒚𝑫𝑫

The method to calculate 𝑓𝑓𝑤𝑤 (𝑦𝑦) in Eq. 18 is a novel method to calculate 𝑓𝑓𝑤𝑤 (𝑦𝑦) based on a

fluence-weighted averaging of constituent 𝑓𝑓(𝑦𝑦). The values for 𝑦𝑦𝐷𝐷 compare closely to those

published by Nikjoo et al, Lindborg et al and Anderson et al [37, 38, 51]. The discontinuities at
100 MeV seen in Fig. 7a), c) and Fig. 8 are due to different energy models in Geant4 DNA
being applied. For protons with kinetic energy < 100 MeV, the DNABornIonisationModel
model is used when calculating energy losses due to ionization. For protons with energies > 100
MeV, the BetheBloch ionization model is used. The calculated 𝑦𝑦𝐷𝐷 values published by Nikjoo et

al at 100 MeV and 200 MeV are 1.8 keV/µm and 0.5 keV/µm, respectively [37]. The 100 MeV

𝑦𝑦𝐷𝐷 for this work was calculated to be 2.13 keV/µm, while the 200 MeV 𝑦𝑦𝐷𝐷 was calculated to be

2.8 keV/µm. A 𝑦𝑦𝐷𝐷 value of about 3 keV/µm at 100 MeV was published by Lindborg et al [38].

The 𝑦𝑦𝐷𝐷 values in this work compare closely to those published by Nikjoo et al and Lindborg et
al at 100 MeV, but there is a large difference at 200 MeV between this work’s 𝑦𝑦𝐷𝐷 and the 𝑦𝑦𝐷𝐷

published by Nikjoo et al. Tsuda et al published a study of the microdosimetry of proton, helium
and silicon ion beams where they compared measured 𝑦𝑦𝐷𝐷 to those calculated by the Monte

Carlo code PHITS [52]. They measured 𝑦𝑦𝐷𝐷 of a 160 MeV proton beam to be about 2.5 keV/µm,

calculated 𝑦𝑦𝐷𝐷 with PHITS to be about 1.98 keV/µm. This work calculated 𝑦𝑦𝐷𝐷 to be 2.56

keV/µm at 160 MeV. Jing Chen published a series of microdosimetry calculations of proton
beams and her 𝑦𝑦𝐷𝐷 values at 500 keV, 2 and 5 MeV closely matched those calculated in this
work [53]. However, at 100 MeV and 200 MeV, Chen calculated 𝑦𝑦𝐷𝐷 at ~5 keV/µm and 4

keV/µm, respectively. The 𝑦𝑦𝐷𝐷 calculated by this work is 2.1 keV/µm at 100 MeV and 2.8

keV/µm at 200 MeV.
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Beyond the discontinuity at 100 MeV, the 𝑦𝑦𝐷𝐷 values calculated in this work are similar

to those calculated in previous works, and similar to those values measured with

microdosimeters such as in Anderson et al [51]. The relationship between LETD and 𝑦𝑦𝐷𝐷 is
9

shown in Fig. 9. Kellerer derived the relationship between 𝑦𝑦𝐷𝐷 and LETD to be 𝑦𝑦𝐷𝐷 = 8 𝐿𝐿𝐿𝐿𝑇𝑇𝐷𝐷 +
3𝛿𝛿2
2𝑑𝑑

, where 𝛿𝛿2 is the weighted energy loss per collision and 𝑑𝑑 is the diameter of the domain [31].

Therefore a linear relationship between LETD and 𝑦𝑦𝐷𝐷 is expected.
4.5 MKM fitting of experimental RBE data

The MK model was applied to the experimental RBE data and the fitting results are
shown in Figs. 10-12. Similar to the generic RBE model, the MK model fit the Guan and Bronk
et al. data poorly (Fig. 10). The MK model performed well with the Patel and Bronk et al data
shown in Fig. 12, as well as both AGO1522 data sets, and the U87 SOBP data from Chaudhary
et al in Fig. 11. Interestingly, the MKM was able to model the fine structure from the SOBP
experiments from Chaudhary et al, where RBE varies more nonlinearly with LETD than in the
pristine Bragg peak experiments. In those experiments the first three RBE points and last three
RBE points seem to be linearly related, but with different slopes. The MK model was able to
capture this fine structure better, most likely due to the fluence-weighted method to calculate 𝑦𝑦𝐷𝐷
proposed in Eq. 18 and Eq. 19. This may also be evidence that 𝑦𝑦𝐷𝐷 is a better metric for

biological effect than LETD. This result should encourage further study of the MKM for clinical
adoption as all proton plans are designed using SOBPs, not pristine Bragg peaks. The best-fit 𝑟𝑟𝑑𝑑
values are shown for each experiment in Figs. 10-12. In this work, 𝑟𝑟𝑑𝑑 varied between 0.202 µm
and 0.461 µm. Other authors have published their 𝑟𝑟𝑑𝑑 values for various cell lines. Kase et al

showed that proton RBE experiments on V79, HSG and T1 cells resulted in 𝑟𝑟𝑑𝑑 values of 0.26
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µm, 0.34 µm, and 0.35 µm [54]. Mairani et al published an 𝑟𝑟𝑑𝑑 value of 0.300 µm for proton and
helium beams [55]. The 𝑟𝑟𝑑𝑑 in this work are thus consistent with previously published values.

The data presented by Guan and Bronk et al and Patel and Bronk et al used the same cell

line, H460. The Patel and Bronk et al data showed a much more linear relationship between
RBE and LETD than the Guan and Bronk et al data, however. The 𝑟𝑟𝑑𝑑 for each experiment was

very different as well. For the Guan and Bronk et al study, the best fit 𝑟𝑟𝑑𝑑 was 0.323 µm; for the

Patel and Bronk et al data, the best fit 𝑟𝑟𝑑𝑑 was 0.426 µm. As Table 9 shows, both of these values

fall outside of the other’s 95% confidence interval. These large differences in 𝑟𝑟𝑑𝑑 are attributed to
the different Monte Carlo settings applied to simulations between the two groups, and the

different methods by which surviving cell colonies were counted between the two studies. Patel
and Bronk et al discuss this Monte Carlo settings issue in detail in their work [19].
4.6 AIC analysis of generic RBE model vs. MK model
Overall the AIC analysis indicated the generic RBE model fit the data best in five
experiments while the MKM fit the data better in two experiments. However, neither model fit
the Guan and Bronk et al data well, so the AIC analysis indicates only a weak preference for the
generic RBE model over the MK model. Based on the AIC analysis there is no clear evidence
that MKM models RBE better than a generic, LETD-based model, for this dataset. Both models
performed well in some experiments, and both models performed poorly in others. This work
has shown that MKM can be applied to proton RBE studies and can accurately model RBE
based on the 𝑦𝑦𝐷𝐷 calculation method presented in section 2.3.3. However, the MK model does
not show a clear superiority in fitting the RBE data as compared to the generic RBE model.

Therefore it is concluded that there is not enough evidence to support moving away from LETD
based proton RBE models that model RBE as a linear function of LETD. There may be some
end of range RBE nonlinearities, and perhaps the assumption of a constant 𝛽𝛽 is flawed, but at
63

present, both the generic RBE model and MKM model provide a sufficiently accurate model of
RBE, even if the underlying RBE model is actually more complex.
4.7 MKM Optimization in matRad
Before proceeding with MKM optimization, a radiation oncologist evaluated the std_opt
plan and gave feedback until the plan was realistic enough to begin variable RBE optimization.
The DVH for the std_opt plan is shown with dashed lines in Fig. 14 and summarized in Table
10. The MK model predicted RBE < 1. 1 throughout most of the brainstem, which led to a
decrease in RWD for the brainstem in the std_opt_MKM_calc plan. The RBE in the GTV and
CTV varied greatly between ~1.0-1.4, with hot and cold RBE spots as shown in Fig. 15. Despite
hot and cold RBE spots, there was very similar RWD coverage between the std_opt and
std_opt_MKM_calc plans: 88.0 % of the GTV got 54 Gy(RBE) in the std_opt plan, and 87.7%
of the GTV got 54 Gy(RBE) in the std_opt_MKM_calc plan. The RWD when calculating RBE
with the MKM was slightly lower in the spinal cord as well. There were hot spots in the CTV
and just outside the CTV in excess of 70 Gy(RBE) that are shown in Fig. 16.
That the RWD in the brainstem decreased when using the MK model is counter to
previous experience with proton irradiation close to the brainstem, where evidence of RBE > 1.1
in the brainstem has been shown [14, 15]. This could be attributed to the choice in 𝑟𝑟𝑑𝑑 for the

brainstem during RBE optimization. 𝑟𝑟𝑑𝑑 was set to 461 nm, but setting it to a smaller value such

as 420 nm (at the lower limit of its 95% confidence interval in the U87 SOBP data in Table 9)

would increase the RBE, as 𝑟𝑟𝑑𝑑 is in the denominator when calculating RBE according to Eq. 14.
Based on clinical experience in irradiating the brainstem it may be more appropriate to select an
𝑟𝑟𝑑𝑑 such that the RBE in the brainstem is ~1.1, and not as low as is shown in Fig. 15.

The brain hotspot in Fig. 16 was removed during the MKM optimization process as

shown in panel b of Fig. 17. Figs. 19 and 20 b show how 𝑦𝑦𝐷𝐷 and the physical dose was
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modulated to decrease the RWD hotspot. One of the most interesting results of the MKM_opt
plan is the increase of physical dose to some regions of the brainstem, shown in Fig. 20 a. Due
to the lower RBE (<1.1) in the brainstem, this led to a lower RWD in the brainstem in the
std_opt_MKM_calc plan, which gave the optimizer freedom to increase physical dose to the
brainstem in the MKM_opt plan. Table 11 shows if the physical dose from the MKM_opt plan
is recalculated using the RBE=1.1 model, the RWD to 0.1cc of the brainstem increases from
56.0 to 59.1 Gy(RBE). This plan would most likely be rejected for having too high of dose to
the brainstem, in addition to having significantly lower GTV and CTV coverage at 54 Gy(RBE).
Without significant evidence of the superiority of using these settings for the MK model, it is
unlikely to be adopted, as the recalculated RWD using the RBE=1.1 model shows a higher dose
to the brainstem than is clinically acceptable. Physical dose was decreased in the hotspot region
shown in Fig. 16 b and 17a, ~6-7 Gy(RBE), shown in Fig. 20 b. Fig. 20a shows the physical
dose was modulated in the same slice shown in Fig. 15, and is consistent with the dose
modulation seen elsewhere in the MKM_opt plan.
The MKM_opt plan resulted in better GTV coverage (94.0% getting at least 54
Gy(RBE) as compared to 87.7% in the std_opt_MKM_calc plan), despite decreasing the
physical dose in some regions of the GTV. The RWD to the spinal cord also slightly decreased
in the MKM_opt plan. The RWD to 0.1cc of the brainstem was increased from 55.8 Gy(RBE) to
56.0 Gy(RBE) in the MKM_opt plan as well. That the RWD increased in the brainstem is a
result of increasing physical dose to the brainstem, despite a decrease of the 𝑦𝑦𝐷𝐷 shown in Fig.

19. The increased physical dose in the brainstem is shown in Fig. 20, while the modulation of
𝑦𝑦𝐷𝐷 between the two plans is demonstrated in Fig. 19.

A useful exercise is to analyze the physical dose distribution given by the MKM_opt

plan, and recalculate the RWD using the standard RBE=1.1 model. This result is shown in Table
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11. GTV coverage at 54 Gy(RBE) drops from 94.0% to 77.5%, and GTV EUD decreases from
58.3 Gy(RBE) to 55.9 Gy(RBE). The CTV coverage deceases significantly as well. The doses
to the brainstem and spinal cord also increase when the MKM_opt RWD is recalculated with
RBE=1.1. The DVH in Fig. 21 shows that by assuming the given MKM parameters during
optimization, the resulting plan may be overdosing the brainstem and significantly reducing
CTV and GTV coverage.
There are a number of issues to be aware of with the MKM optimization algorithm written
into matRad in this work that need to be addressed before clinical implementation. They
include:
1) The high RBE values seen in experiments such as in Refs. 17-19 occur only along the
distal falloff region of the Bragg peak or SOBP. The rapidly rising RBE occurs within a
fraction of a millimeter, in the falloff region where the dose drops dramatically across
that same distance. Voxel sizes in patient planning CTs are on the order of 1 mm, so
these high RBE regions are likely to be lost due to volume averaging.
2) In this project, the 𝑟𝑟𝑑𝑑 for specific tissues were assumed to be the same as they are for the
U87 glioma and AGO1522 fibroblast data from Ref. 17 fit for the MK model presented

in this work. These values have not been clinically validated, although a similar 𝑟𝑟𝑑𝑑 value

(320 nm) was used by Inaniwa et al in their study for using MKM in the research version
of their carbon ion treatment planning system [43]. Based on RBE values in the
brainstem much less than 1.1, it is appropriate to reevaluate the 𝑟𝑟𝑑𝑑 value for the
brainstem. 𝑟𝑟𝑑𝑑 should be a smaller value, perhaps around 420 nm. The result of

calculating RBE in the brainstem to be mostly ~1.0 demonstrates the danger in
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translating the fitting parameters of RBE experiments directly into a TPS. All
radiobiological parameters should be fully evaluated before clinical implementation.
3) The 𝛼𝛼0 values used for RBE optimization marked a change from the method of using 𝛼𝛼𝑥𝑥
laid out in Chapter 2.2-2.4. This reflects a changing concern over the course of this

multi-year project that RBE experiments widely differ in the reference radiation used.
For instance, in the RBE data in Ref. 17, 225 kVp x-rays are used and in Ref. 18 and 19,
Cs-137 irradiation is used. In the method laid out by Frese et al in Ref. 45, 𝛼𝛼0 has been

adjusted from 𝛼𝛼𝑥𝑥 to remove dependence on LET. Using 𝛼𝛼0 is most consistent with the
theory of the MKM, and so is used for treatment plan optimization. However the

difference between 𝛼𝛼0 and 𝛼𝛼𝑥𝑥 in Frese et al’s data are small and the difference in RBE

between the two values would be negligible.

4) Using a RBE defined as the dose required to reach a clonogenic cell survival fraction of
10% may not be the most accurate representation of RBE effects in vivo. Other RBE
endpoints such as intestinal crypt cell regeneration, single or double strand break
induction, foci of DNA repair proteins and chromosome aberrations have all been used
as endpoints to model RBE [56, 57]. Overall, the alternate endpoints do not disagree
with the current RBE=1.1 model, although some selected endpoints did show
considerable differences. Other clinically-relevant endpoints include standardized
cognitive tests, inflammation and late tissue reactions, and these are not addressed by the
MK model [42].
5) When creating the patient treatment plan, the exact beam geometry (beam angle and
couch angle) the patient was treated with was used for IMPT optimization. These may
not be the ideal angles for biologically-optimized IMPT treatments.
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6) The method to calculate 𝑦𝑦𝐷𝐷 𝑚𝑚𝑚𝑚𝑚𝑚 is very similar to using LETD, whose drawbacks have

been written about extensively [11, 12]. As proposed in this work, calculating 𝑦𝑦𝐷𝐷 based
on the proton energy spectrum may be a more accurate way to model biological effect.
However with the present computational and software resources, it is not feasible to
compute the proton energy spectrum in every voxel in the planning CT fast enough to be
useful for optimization. GPU-based Monte Carlo systems may be fast enough for clinical
implementation, however [58].

7) Neither of the two optimized treatment plans (std_opt or MKM_opt) were robustly
optimized, either for physical dose or biologically. Including robust optimization would
greatly increase the optimization time.
8) The IMPT plans (std_opt and MKM_opt) were probably not the best IMPT plans that
could be created, due to the author’s inexperience with treatment planning. However, the
purpose of comparing a standard RBE=1.1 treatment plan to one with variable RBE is
meant to illustrate the possible benefits of including variable RBE in optimization;
namely enhanced GTV coverage and increased sparing of normal tissues. MatRad lacks
many features of commercial treatment planning systems that users can utilize to fine
tune the dose distribution of plans. With more time and skill, more clinically realistic
plans could be created.
9) Despite the large discontinuity in 𝑦𝑦𝐷𝐷 at 100 MeV (Figs. 8 and 13), this discontinuity will
have a minor effect on the RBE calculation in matRad. When taking the case of

predicting RBE in H460 cell line using MKM, 𝛼𝛼𝑥𝑥 = 0.29 Gy-1 and 𝛽𝛽𝑥𝑥 = 0.083 Gy-2. By

taking two 𝑦𝑦𝐷𝐷 values of 0.5 keV/µm and 2.8 keV/µm and inputting those parameters into
Eq. 14 and Eq. 15, then calculating RBE according to Eq. 20, when 𝑦𝑦𝐷𝐷 = 0.5 keV/µm,
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RBE = 1.013. When 𝑦𝑦𝐷𝐷 = 0.5 keV/µm, RBE = 1.073. So even though 𝑦𝑦𝐷𝐷 changes by a

factor of almost six, RBE changes only by about 6%. This is a result of the MKM

assumption of the insensitivity of 𝛼𝛼𝑝𝑝 to changes at low 𝑦𝑦𝐷𝐷 values, from Eq. 14. If the

disagreement between 𝑦𝑦𝐷𝐷 were to occur at lower energies, where 𝑦𝑦𝐷𝐷 might be 10 vs 60

keV/µm, the resulting RBE values would be 1.27 and 2.96, respectively. However, the

discrepancy is at high energy and relatively low 𝑦𝑦𝐷𝐷 only. Thus it can be concluded that

despite the large discontinuity in 𝑦𝑦𝐷𝐷 values as a result of different physics lists applied to
Geant4 DNA, this creates a negligible change in RBE values during treatment planning
in matRad.

10) An issue with the implementation of the biological optimization algorithm implemented
into matRad is the length of time and computational resources it took to create the
MKM_opt plan. Starting from the result of the std_opt_MKM_calc plan, a biologically
optimized plan took ~17.2 hours to run, and required up to 104 GB of memory. If the
plan has to be fine-tuned to be accepted for treatment, the plan will need to be optimized
several times. However this could be somewhat mitigated by optimizing the code for
speed, by modifying it to utilize GPU technology, or Matlab’s multithreading capability.
Despite these drawbacks however, the RBE optimization algorithm was able to take RWD
hot spots in normal tissue and modulate the physical dose and 𝑦𝑦𝐷𝐷 to create a superior plan in
MKM_opt, compared to the std_opt_MKM_calc plan, in terms of GTV coverage while still
adhering to OAR dose constraints. Fine tuning the parameters for 𝑟𝑟𝑑𝑑 , 𝛼𝛼𝑥𝑥 and 𝛽𝛽 to more

clinically-realistic values may lead to a decrease in the superiority of the MKM_opt plan, but
there may still be some room for improvement over plans optimized using the static RBE=1.1
model.
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The AAPM TG-256 report summarizes the current state of proton RBE research [57]. One
of the conclusions of the report is that based on current uncertainties in modeling RBE in
normal tissues and tumors, the adoption of a clinical RBE model is premature. The RBE
optimization algorithm presented here does not solve the uncertainty issues presented in TG256, but it does mirror the conclusion of the report, that it is theoretically possible to use an
RBE model in treatment plan optimization that decreases the RWD to critical structures while
increasing the RWD to the GTV.
There are other methods to incorporate RBE into the optimization process that are short of a
full RBE model such as the MKM. The LET distribution can be optimized to put high LET
regions of the beam into the GTV and CTV, and push the low LET regions into normal tissues
without significantly changing the physical dose distribution [59]. Another method is to use an
LET-weighted dose model that models RBE as a function of LET [60]. Others have also
proposed introducing track-end objectives into optimization, where proton track ends are
terminated preferentially in the target and LET in normal tissues is decreased, without changing
the dose to the target [61]. These approaches can take into account the variation in RBE with
LET while avoiding the more serious uncertainties that currently plague a clinical
implementation of a proton RBE model.
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Chapter 5: Conclusion
5.1 Difference between phenomenological models and experimental RBE data
The hypothesis of Specific Aim One was that phenomenological RBE models will
underestimate RBE in the Bragg peak and distal falloff region by 20% or more. In total, three
RBE models were applied to RBE datasets and as a result, 93 predictions about RBE were made
by phenomenological models. Of these 93 RBE predictions, 43 model predictions underestimate
RBE by 20% or more. There is a wide range in quality of model fitting to the experimental data.
For instance, the U87 cell line from Chaudhary et al is modeled well by all phenomenological
models while the AGO1522 cells from the same study are poorly modeled by the models. The
phenomenological models fit the experimental data of Patel and Bronk et al well, but not the
data presented by Guan and Bronk et al, even though both studies utilized the same cell line. As
a result of these findings, the hypothesis of Specific Aim One is accepted. In nearly half of the
RBE data points, phenomenological RBE models underestimate experimental RBE by more
than 20% in the Bragg peak and distal falloff region.
5.2 Comparing the MK model to a generic LETD based RBE model
In Specific Aim Two, the hypothesis was that the proposed method to calculate 𝑦𝑦𝐷𝐷 and

input into the microdosimetric kinetic model would predict RBE at all experimental points

within experimental uncertainties. As shown in Figs. 10-12 the MK model was unable to model
RBE within experimental uncertainties in all experiments. Thus the hypothesis of Specific Aim
Two is rejected. A goal of Specific Aim Two was to determine the optimal fitting parameters for
the MKM. The optimal fitting parameters found for this work are similar to those published by
other authors, and this was deemed a success.

71

5.3 Creating biologically-optimized treatment plans with matRad
The goal of Specific Aim Three was to implement a variable RBE optimization
algorithm into matRad to create biologically optimized IMPT plans, and to determine if such an
algorithm can create plans that will both increase target coverage while sparing OARs. The
treatment plan example demonstrates that the RBE optimization algorithm was implemented
successfully, and that biologically optimized IMPT plans can, in theory, be superior to plans
optimized using the RBE=1.1 model. The advantage of these biologically optimized plans is
slight, however, and a number of assumptions have been made. These assumptions have to be
evaluated through clinical trials before being adopted for widespread use. However, this work
has shown that in theory, biologically optimized IMPT plans can be superior to conventionally
optimized plans that assume a constant RBE of 1.1 Therefore this aim is completed
successfully.
5.4 Future directions
There are a number of improvements and continuations of this work. The question of
whether or not RBE is a linear function of LETD or 𝑦𝑦𝐷𝐷 is still unanswered, and more

experiments are needed to answer this question. High precision RBE measurements such as
those in Refs. 17-19 and proposed by Guan et al [62] will shed light on the RBE-LET
relationship. Modeling RBE with the MK model can serve as a test of the linearity of RBE as
well. The work presented here could also be expanded to other cell lines, and cells that have
already been studied with MKM such as V79, T1 and HSG to determine the variability of 𝑟𝑟𝑑𝑑 in
different experiments for the same cell line, as has been done with H460 in this work. The

method to compute 𝑦𝑦𝐷𝐷 can also be expanded into heavier ions such as carbon and helium, and
RBE could be modeled in a similar way to this work. For heavier ions, a saturation correction
would have to be included to model the overkill region.
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A very promising research area is the biological optimization of treatment plans. This is
a topic with considerable interest for proton therapy, but is underdeveloped. Future work could
adapt this RBE calculation method into a commercial TPS and use that to do a more in-depth
comparison of treatment plans using variable RBE and constant RBE of 1.1 One assumption
made in the RBE calculation in matRad is the appropriateness of dose averaging of 𝑦𝑦𝐷𝐷 from

different pencil beams. The RBE calculated via the algorithm implemented into matRad should
be compared to a Monte Carlo simulation of the proton energy spectra in each voxel, where 𝑦𝑦𝐷𝐷
is calculated from Eq. 18 and Eq. 19. This would highlight differences between the two

calculation methods and may provide insight as to the drawbacks of calculating RBE via the
MK model and Eq. 26. A fuller assessment of the tissue-specific MKM parameters for 𝑟𝑟𝑑𝑑 , 𝛼𝛼0
and 𝛽𝛽 also needs to be completed before this algorithm can be implemented clinically.
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